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ABSTRACT OF DISSERTATION

THE ROLE OF PRO-INFLAMMATORY MEDIATORS
IFNβ AND PROSTAGLANDIN E2
IN SUPPRESSION OF INNATE IMMUNITY TO
LISTERIA MONOCYTOGENES

As a foodborne pathogen, Listeria monocytogenes (Lm) encounters many barriers to
invasion and dissemination in the host that may change the nature of host response. Lm has been
most commonly studied using intravenous (i.v.) inoculation, however, a method that delivers a
bolus of bacteria directly to the bloodstream. Thus, little is known about what systemic and local
mediators are triggered during the natural course of infection and how these may impact
susceptibility. Our laboratory used foodborne transmission of Lm in mice to assess whether the
method of transmission and the specific organ microenvironment could affect infection-induced
secretion of type I interferon or prostaglandin E2. Type I interferon is a pro-inflammatory
effector secreted in response to viruses that has been proposed to paradoxically down-regulate
innate immunity to intracellular bacteria. In contrast to i.v. infection, type I interferon was not
detrimental to the immune response when Lm were acquired orally. In fact, most of the antiinflammatory effects of type I interferon in the spleen were attributable to i.v. but not foodborne
infection. Importantly however, downregulation of the receptor for interferon gamma (IFNGR1),
previously ascribed to the type I interferon response, was found to be a consequence of infection
and unrelated to type I interferon. In the liver, robust recruitment and activation of neutrophils
(PMN) is thought to be required for initiation of Lm immunity. Prostaglandin E2 (PGE2) is a
lipid mediator most commonly associated with pain and fever that has also been demonstrated to
have anti-inflammatory or tolerogenic effects. It is unknown, however, whether foodborne
infection induces PGE2 in the liver and if PGE2 then down-regulates PMN activities.
Recruitment of PMN to the liver following foodborne infection was robust in both susceptible
and resistant animals. Bone marrow PMN from each killed Lm ex vivo with similar efficiency,
thus suggesting that if PMN were dysfunctional during the course of natural infection, they were
responding to cues in the microenvironment. Accordingly, significantly more PGE2 was made ex
vivo by cells from the livers of susceptible animals than from resistant animals. When PGE2 was
applied to naïve PMN prior to exposure to Lm, it consistently dampened the killing efficiency of
these cells, suggesting that this lipid better known for its pro-inflammatory roles might have antiinflammatory effects during Lm infection. Overall, these studies indicate that mediators produced

as a result of infection may have very different roles dependent on route of inoculation, timing,
and the specific organ examined.

KEYWORDS: innate immunity, neutrophil, prostaglandin E2, type I interferon, Listeria
monocytogenes
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1. Introduction
1.1 Epidemiology
Listeria monocytogenes (Lm) is a gram-positive facultative anaerobe often found in the
soil and decaying vegetation (1, 2). Lm is the causative agent of listeriosis, a rare but very serious
disease that may afflict humans and grazing mammals. In addition to Lm, more than ten other
members of the Listeria genus have been identified, but only Listeria ivanovii is recognized as
pathogenic. Thirteen serotypes of Lm have been described, with four causing most cases of
human disease. The commonly used laboratory strain EGDe is one of these four, serovar 1/2a. A
recent study, however, found that the reference strains EGD, EGDe, 10403s, and LO28 may all
be hypovirulent in comparison to clinical isolates belonging to other clonal complexes (3).
It is estimated, using fecal carriage studies, that most people will consume Lmcontaminated foods between 5 and 9 times a year (4). Lm is a common contaminant of fresh
produce, nuts, smoked fish, and dairy, and is annually responsible for many national and
international recalls of both human and animal food products. In late 2017-early 2018, a massive
outbreak occurred in South Africa that as of April 2018 had cause 189 deaths from an astounding
982 laboratory-confirmed cases (5). The outbreak was associated with consumption of a food
product called polony, and whole genome sequencing of bacteria isolated from both the
production plant and the finished product confirmed genetic relatedness of the isolated bacteria.
In 2016, Lm accounted for a staggering 81% (47 million out of 58 million total pounds) of the
total amount of food recalled by the USDA, thanks in large part to contamination of frozen
vegetable products produced by one company (6). Nine people in four states were hospitalized
and diagnosed with listeriosis linked to the isolates from these products with three deaths, one of
which was confirmed to be directly caused by listeriosis (7). Another notable recall occurred in
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2015, when Blue Bell Creameries voluntarily recalled all of its products and shut down
production following a multi-state outbreak with three deaths. All of the diagnoses, 10 in total,
were made in patients who were already hospitalized for unrelated conditions and six of these
people were positively determined to have consumed products made from the contaminated ice
cream (8). This outbreak underscored the idea that although Lm is commonly consumed, some
level of immune compromise or genetic predisposition is generally required for invasive disease
to develop.

1.2

Clinical disease and treatment
For the majority who ingest Lm, the only symptoms that materialize will be self-limiting

gastroenteritis or flu-like symptoms (9). In the elderly, however, or in patients with comorbidities
such as HIV, cancer, diabetes mellitus, and those on immunosuppressive therapies, the disease
may progress to invasive listeriosis, characterized by septicemia, meningitis, and/or encephalitis,
before diagnosis is made (9). A recent study found that because a diagnosis of invasive listeriosis
generally results in admission to intensive care, it is the third most costly foodborne pathogen in
the US (10).

Fortunately, Lm is susceptible to a wide range of antibiotics, including

trimethoprim–sulphamethoxazole and β-lactams, and provided that proper treatment is initiated
early, many who are diagnosed will recover. Once the bacteria have crossed the blood-brain
barrier, however, treatment becomes more difficult and outcomes are generally less favorable
(11).
In humans, listeriosis presents most often in immunocompromised or elderly individuals
as sudden-onset meningitis or septicemia and has an annual mortality rate averaging 25% of all
diagnosed cases (12, 13). There are also cases noted in adults with no known pre-disposing
conditions and otherwise healthy immune systems, suggesting that a genetic component may
contribute to susceptibility, or that a dose threshold exists, below which most symptoms will be
2

self-limiting in immunocompetent individuals. The infectious dose needed for listeriosis to
develop is not well understood overall. The recent ice cream outbreak, however, provided
investigators with an opportunity to assess Lm levels in a frozen product, where Lm is fully
capable of persisting but does not grow. Testing products manufactured before the outbreak on
the same production line as the implicated products found an average of 380-2100 CFU per 80gram unit of product (14). This is a startlingly low number; previously the infectious dose for
healthy individuals was estimated to be 10 to 100 million organisms, and for
immunocompromised people was estimated at 0.1 to 10 million (15). The incubation period, or
the time between ingestion of Lm and illness, is also not well-understood, thanks in large part to
the wide variety of foods which Lm can be found in. A recent French study which identified 37
cases from investigations carried out by the French National Institute for Public Health
Surveillance found a wide range of incubation periods. Gastroenteritis was observed in as little as
24 hours, central nervous system and bacteremia cases in 1-14 days, and pregnancy-associated
cases presented between 17-67 days after suspected ingestion of contaminated foods (16).
Listeriosis is a serious concern during pregnancy, necessitating a long list of foods that
are “off limits” during pregnancy.

Pregnant women may themselves only develop flu-like

symptoms; however, spontaneous abortion, pre-term birth, and neonatal infection are all potential
complications for the pregnancy (9, 11, 13). Recently, a cohort study encompassing 818 cases
found that one-quarter of diagnosed pregnant women experienced fetal loss prior to 29 weeks of
gestation (11).

3

1.3

Virulence characteristics

Environmental adaptations
Lm has evolved characteristics that make it both environmentally hardy and insidious in
human disease. A saprophyte, Lm has been found in a variety of soils and tested to survive under
a wide range of soil conditions (1, 2, 17). As such, it is commonly found contaminating dairies,
fresh produce, and silage (fermented ruminant feed). Lm is able to rapidly transition from its
environmental state into an infective state, a process that requires multiple changes in gene
regulation in response to changes in temperature, pH, oxygen saturation, and osmolarity. Two
transcription factors- the stress response alternative sigma factor σB, and PrfA, control the
majority of these adaptations (18, 19).
Johannson et al. showed that PrfA was controlled by a 5’ UTR thermosensor, which
adopted secondary structures at various temperatures to ensuring that the virulence genes
regulated by PrfA are upregulated at 37°C (20). However, this thermoregulation is thought to
produce a low, basal level of PrfA only, as intracellular conditions further upregulate PrfA and
transcription of the virulence genes that it controls (21). PrfA regulates genes encoding two
phospholipases; actA, which encodes the actin-polymerizing protein ActA; hly, which encodes
the cholesterol-dependent pore-forming toxin listeriolysin O (LLO), and mpl, a metalloprotease.
Loss of any of these genes significantly attenuates Lm virulence; for example, ∆hly mutants
cannot escape from the phagosome and thus are completely avirulent (22).
The transcription factor σB regulates a number of genes useful in environmental stress
responses, including a glutamate decarboxylase, involved in acid resistance, and a bile sale
hydrolase (21). Additionally σB was shown by Nadon, et al. to regulate transcription of one of
the prfA promoters in vitro, thus the expression of prfA- mediated virulence genes is at least
partially dependent on σB (23).

4

Invasion factors
Lm appears to use two primary invasion factors, known as internalins (Inl), to gain access
to cells. Although there are more than 20 cataloged internalins, InlA and InlB are the two major
invasion factors (24-27).

InlA is a cell-wall anchored protein that interacts with E-cadherin to

facilitate uptake into enterocytes and goblet cells (27). Addition of InlA to Listeria innocua, a
normally non-invasive member of the genus, allowed this bacteria to gain receptor-mediated
entry into Caco-2 cells, which are similar to human intestinal epithelial cells (24). E-cadherin,
however, is a major component of adherens junctions, the side-to-side connections of epithelial
cells, and is not normally accessible from the intestinal lumen. Pentecost et al. showed that rather
than disrupting epithelial barrier integrity in the intestine to access E-cadherin, Lm instead uses
the self-renewing nature of enterocytes to its advantage (28). When a cell is normally extruded,
E-cadherin is transiently exposed to the lumen and becomes accessible to Lm. Thus, the bacteria
triggers its own uptake without activating host surveillance mechanisms.

InlA- E-cadherin

interactions are very species-specific, however, and wild type mice do not express the form of Ecadherin that InlA naturally binds (29, 30), making oral infection of mice inefficient.
Experimental methods used to alleviate this difficulty are discussed further under section 1.4,
“Transmission method.”
InlB binds Met, a receptor tyrosine kinase, on a variety of cells including hepatocytes,
and also activates cell signaling mechanisms not triggered by InlA (24, 31, 32). In vitro, inlB
expression was found to be necessary for hepatocyte tropism; however, Gregory et al. showed
that the inlAB operon was not necessary in vivo for infection of hepatocytes (33). It remains
unclear, however, what other routes Lm might use to access hepatocytes.
Deletion of inlA was shown not to affect bacteria levels in the spleen and liver following
oral infection of mice (34, 35). Lm have also been shown in vitro to translocate across intestinal
M cells independent of internalin function or secretion of the pore-forming toxin LLO (36). This
5

suggested that Lm utilize other methods to gain access to the intestinal lamina propria. Drolia et
al. recently reported that LAP (Listeria adhesion protein) binding of HSP-60 on intestinal
epithelial cells triggers NFκB signaling in the cell and rearrangement of cell-to-cell adhesion
proteins, thus allowing Lm to translocate across the epithelium (37). In this study, ∆lap Lm
exhibited a significant defect in dissemination to the spleen and liver, more so than the ∆inlA
strain.
Cell-to-cell spread
In vitro infections as well as extensive work done using i.v. infection of mice has shown
much of how Lm escapes from the phagosome and begins cell-to-cell spread. Key virulence
factors LLO and PLC function in a complementary manner to facilitate Lm vacuolar escape. If
not rapidly killed once internalized, Lm utilizes LLO and PLC to lyse the vacuole membrane and
escape to the cell cytosol (38-41). Secreted PLC also induces phagosomal assembly of NADPH
oxidase, a process which secretion of LLO was also recently shown to prevent (42). To move
from one adjacent cell to another, Lm uses ActA to polymerize host cell globular actin into
filamentous F-actin, forming the “comet tails” commonly seen in micrographs and
immunofluorescent images of intracellular Lm (43, 44).

Extensive work by several groups

including Tilney and Portnoy (44) showed that actin was polymerized on one pole of the
bacterium, thus allowing Lm to move away from the building actin tail. In confluent or adjoining
cells, once the tail reaches the cell membrane, Lm protrudes into a neighboring cell and is
eventually taken into that cell, forming a double-membrane vacuole which is again lysed by LLO
and PLC (41, 44). This is a particularly useful trait in tissues such as the hepatic parenchyma,
where it can infect large areas of hepatocytes without needing to encounter complement or
phagocytic cells.
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1.4

Mouse Model

Differential susceptibility in mice
In order to compare characteristics that might affect infection in susceptible and resistant
individuals, two mouse strains are commonly used: susceptible BALB/cBy/J (BALB) and
comparatively resistant C57BL/6. (B6) Using intravenous (i.v.) infection, Cheers et al. found that
the LD50 for B6 mice was 100-fold greater than that of BALB mice. When these two strains were
crossed, approximately half of the offspring became resistant, leading to the idea that there was a
dominant resistance gene in the B6 mouse (45). Later, the same group showed that overall
clearance kinetics in the spleen and liver were slowed in the BALB mouse and that early bacterial
burdens grew differently in the liver than in the spleen (46). At 24 hours post infection with 104
Lm, approximately 10-fold more bacteria were present in the livers of BALB mice than in B6,
whereas burdens were very similar at this point in the spleen. This suggested that a differential
early clearance response had taken place in the liver, and the authors speculated that macrophage
uptake of Lm in the BALB liver could be deficient (46).
Overall, most susceptibility differences between mouse strains have been attributed to
facets of innate immunity, including differential expression of STAT4 and reduced or delayed
secretion of TNFα, IL-12, and IFNγ (47-50). The conventional view is that when infected with
Lm, BALB mice initially tend to produce a Th2 response, which is useful for extracellular
pathogens and parasites, while B6 mice respond with secretion of Th1 cytokines including IFNγ.
Both BALB and B6 mice carry a non-functional allele for NRAMP1, a protein associated with
natural resistance to intracellular bacteria, and are complement-sufficient (51, 52). A study
utilizing F2 progeny of BALB and B6 matings mapped susceptibility loci to chromosomes 5 and
13, designated Listr1 and Listr2 (53). Later, expression of CXCL11 was mapped to the Listr1
loci on chromosome 5. (54) Mice carrying the locus had significantly higher hepatic bacterial
burdens at 24 hours post infection than the control strain, a difference thought to be due to the
7

presence of fewer CD14+ liver-resident mononuclear phagocytes. Notably, this locus had no
effect on bacterial burdens in the spleen. Another study co-localized the diabetes susceptibility
allele Idd14 in non-obese diabetic (NOD) mice with Listr2 (55), thus adding NOD mice to the list
of Lm-susceptible animals.

In general, however, the majority of studies of Lm susceptibility

have used BALB or B6 mice and their derivatives, as these two display the largest difference in
susceptibility. Despite extensive study over the past several decades, though, many important
components of innate immunity to Lm such as the neutrophil response have not been compared in
these mice.

Sex-based susceptibility
Sex-based susceptibility of mice to Lm has not been as clearly defined as strain
susceptibility. In humans, gender is often identified as a risk factor for many diseases including
those of infectious origin; however, a clear gender preference has not been identified in listeriosis
cases. An early study by Cheers et al. found no difference in susceptibility in any of the mice
tested (45), while a much more recent investigation showed that female mice of any strain were
significantly more susceptible to Lm infection than males. This difference was thought to be a
result of increased serum IL-10 (56). When foodborne infection was used, BALB females were
more susceptible than males, but interestingly, no sex-based differences were seen in B6 mice
(35). For ease of study and to lessen the chances of fighting amongst cage mates, female mice
were often used in the studies detailed in the later chapters. However, male mice were also used
where available or appropriate, and no significant differences in susceptibility, cell function, or
cell yield per gram of body weight were noted between sexes in these studies.
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Transmission method
Lm has long been studied as a model intracellular pathogen in mice by using intravenous
infection, a highly reproducible method that has led to the advancement of knowledge in many
areas of immunology. Intraperitoneal infection has also been widely used because of its ease and
reproducibility.

However, with the exception of maternal-fetal vertical transmission, Lm is

exclusively acquired in humans by the consumption of contaminated food. Oral infection of mice
is most commonly done by intragastric (i.g.) inoculation, a process that is extremely investigatordependent, and may even induce rapid blood borne spread by esophageal tearing (57).
Furthermore, i.g. inoculation is thought to decrease transit time through the stomach and small
intestine, resulting in a large percentage of the inoculum being shed in the feces. Lecuit et al.
observed that a single amino acid in E-cadherin was responsible for the species specificity of InlA
(30). Shortly thereafter, this group created a mouse expressing human E-cadherin in enterocytes
and observed that this single change allowed significantly more bacteria to translocate across the
intestinal epithelium, creating immune responses and pathologies not seen with the ∆inlA mutant
(29). More recently, inlA was murinized by point mutation, creating “inlAm” (58). This allowed
interaction with mouse E-cadherin and therefore the use of lower and presumably more
physiologic doses. However, murinization was also found to increase the receptor repertoire of
InlAm by allowing binding of N-cadherin and furthermore to create inflammation not previously
noted (59, 60). It is unclear though what effect this altered tropism has, as murinized and nonmurinized strains of Lm were recently found to spread beyond the intestine in a similar manner
(61).
In order to study natural dissemination, Bou Ghanem et al. developed a foodborne
method of Lm transmission that more accurately recapitulates the events of infection than other
transmission methods (35). After i.v. infection, approximately 90% of the original inoculum is
found in the liver only minutes after infection (62-64). The burden quickly begins to grow,
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peaking at approximately day 3 before clearance mechanisms overcome the rapid bacterial
growth. Cheers et al. showed in 1979 that an i.v. dose of 1.2 x 103 Lm yielded an infection that
peaked at day 2-3 in the spleens and livers of BALB and B6 mice. Clearance was observed in the
spleen by day 6 in both mice, but BALB livers were still significantly infected at day 6 when the
burden in B6 livers had dropped below the limit of detection (46). D’Orazio et al. showed later
that an i.v. infection of BALB mice with 2 x 103 CFU yielded a similar peak day, although
burdens were approximately 10-fold higher (65). However, this study showed that burdens were
not cleared from either organ until approximately day 14. This is a striking difference from the
earlier study, one that might potentially be explained by the Lm strain used; however, it is
unknown what strain was actually used in the 1979 study.
Using foodborne transmission and a dose of ~5 x 108- 1 x 109 CFU, a very low number of
bacteria are sometimes found in the liver at 6 hpi, with burdens below the limit of detection at 24
hpi, indicating that early innate clearance mechanisms are sufficient to remove low numbers of
bacteria (D’Orazio, SEF, unpublished data). This is likely due to direct transit from the intestinal
tissues to the liver via the portal vein. The burden does not grow to appreciable numbers until at
least 48 hpi with a peak typically at 5 dpi ((35), Pitts unpublished observations). This difference
is because Lm must cross many barriers to dissemination and either establish a fulminant
infection in the intestinal tissues followed by spread to the liver or be carried to the liver via
portal vein circulation (depicted in Fig. 1.1 and discussed further in “Spread beyond the
intestine”). Clearance after the peak burden is achieved is relatively rapid in the B6 mouse,
happening at approximately eight dpi in most tissues. In the BALB, the comparatively higher
burdens are cleared more slowly, with most organs still bearing high burdens at eight dpi,
especially if the infection is done during the mouse’s dark cycle (35). In order to observe similar
bacterial burdens in the spleen when comparing i.v. and foodborne infection, it is necessary to
modulate the dose and timing as was done in Chapter 3. Here, B6 were either infected i.v. with
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104 CFU and spleens were harvested at 1 dpi or infected by foodborne transmission with 109 CFU
and spleens were harvested at 3 dpi. Although not identical, this produced similar CFU burdens
in the spleen at harvest because of the different kinetics of each infection.
Although foodborne transmission of Lm is much more relevant to study of the natural
course of infection than other methods, it is not without hurdles, particularly with regard to
natural variation from mouse-to-mouse. CFU burdens within a group of mice may vary by 10fold or more, for example. Simple techniques to overcome some of these hurdles, such as fasting
mice overnight prior to infection and housing mice for the duration of the infection on raised wire
floors to prevent coprophagy, can overcome these issues however.

1.5

Innate immunity to Lm

Uptake
Lm may be phagocytosed by professional phagocytes such as neutrophils (PMN) and
macrophages or taken up by activating internalin- dependent mechanisms in non-phagocytic cells
(32, 66).

Complement opsonization, the decoration of the surface of a pathogen with

phagocytosis-enhancing proteins, is not necessary for phagocytosis of Lm but was shown to
greatly improve phagocytosis efficiency of human cells (67). Some discrepancies between work
done with mouse and human cells exist, however. Baker et al. showed that cell wall components
of Lm activate the complement system via the alternative pathway in mouse serum (68).
Activation of the complement by the alternative pathway in human serum has also been described
(69), but another group found no role for the heat labile component of serum in opsonization (70).
A role for complement and IgM, but not IgG, in opsonization of Lm was also described by
Bortolussi et al. (67). Regardless of any potential differences between mouse and man, however,
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complement appears to play a major role in opsonization of Lm where Lm-specific antibodies are
not present.

Spread beyond the intestine
Orally acquired Lm must first pass through the acidic environment of the stomach,
thought to kill the majority of bacteria, and then gain access to the intestinal lamina propria (35,
71) before being transported to the liver via the portal vein or the lymphatics (depicted in Fig.
1.1). Melton-Witt et al. used signature-tagged infection of guinea pigs to estimate that only 1 in
106 ingested bacteria reach the lamina propria (72), therefore, portal vein transport of large
numbers of intact bacteria simultaneously from the intestine to the liver is likely to be a rare
event. Lm not transported through portal circulation must disseminate to the mesenteric lymph
nodes, avoid killing by phagocytes, and then move into general circulation through the lymphatic
fluid before accessing the liver and spleen.
It is unclear how Lm spread from the intestine to the mesenteric lymph nodes. Lm is
considered a primarily intracellular pathogen, yet studies have found significant percentages of
extracellular bacteria after both i.v. and foodborne infection. Glomski et al. showed that many
bacteria in both the spleen and the liver after i.v. infection were sensitive to both gentamicin and
the presence of neutrophils, indicating that the bacteria were extracellular (73). The bacteria may
also replicate extracellularly in the gall bladder, allowing them to re-seed the intestine as bile is
released with each meal (71). Jones et al. observed that the majority of the intestinal burden after
foodborne infection was extracellular and that likewise, most of the bacteria in the lymph nodes
were not inside a cell (74). Lm was also found to primarily associate with monocytes in the
intestine and mesenteric lymph nodes, but the cells were not efficiently infected, casting doubt
that intracellular transport in monocytes was a primary route of dissemination (75).
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I.v., i.p. (intraperitoneal), and i.g. methods all fail to replicate the natural course of
infection and therefore, little is actually known about the immune response to ingested Lm. I.v.
infection rapidly seeds the liver with up to 90% of the inocula, with the remainder largely
entering the spleen (62-64). Studies using i.v. infection have found that bloodborne Lm are
initially trapped by resident macrophages in the liver and spleen (63, 64, 76). Kupffer cells (KC),
the resident macrophages of the liver, trap up to 90% of bloodborne bacteria, with the remainder
trapped by marginal zone macrophages of the spleen (64). KC were shown to inactivate the
majority of the bacteria ingested, while marginal zone macrophages do not do so until they
encounter IFNγ (64). Regardless, as a result of encountering sequential bottlenecks, ingested Lm
are likely to arrive at the liver and spleen asynchronously and in much smaller numbers than after
i.v. infection and activate innate immunity more slowly. If i.g. inoculation is employed, or if very
high doses are used, rapid seeding of the liver may be observed. This has been speculated to be a
result of direct bloodstream invasion after esophageal tearing, in the case of i.g. inoculation, or
due to large numbers of bacteria gaining access to portal circulation if overwhelming doses are
used (77).

Innate immunity in the spleen
The spleen is not required for the initial stages of the immune response to Lm; however,
splenectomized mice fail to develop adaptive immunity to i.v. Lm and are thus susceptible to
reinfection (76). Splenic marginal zone macrophages, which recognize bacteria through several
receptors, move into the white pulp after ingesting Lm, where they begin to establish foci of
infection characterized by recruitment of PMN and monocytes (76, 78). Lm-specific CD4 and
CD8 T cells can be found in the white pulp after 24 h of infection, indicating rapid antigen
processing once the phagocytes move into the white pulp (76). When mice were given a very
high dose i.v. infection in order to more effectively visualize bacteria, PMN began to accumulate
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in the marginal zone and red pulp of the spleen within 6 h of infection and continued to infiltrate
until 2 dpi, extending into the white pulp as the CFU burden grew (76).
Large numbers of splenic lymphocytes undergo apoptosis as Lm enters the white pulp, a
process attributed to induction of type I interferon (discussed in section 1.7 and chapter 3) (79).
Carrerro et al. showed that SCID mice, which lack lymphocytes, were paradoxically more
resistant to i.v. Lm, suggesting that the lymphocyte apoptosis induced in the spleen was
negatively regulating immunity. This study also found that IL-10 induced after apoptosis was a
key regulator of anti-Lm immunity (79).
As with most intracellular pathogens, interferon gamma (IFNγ) is critical for innate
immunity to Lm and is secreted by CD8+ T cells and NK T cells following infection in an IL-12
and IL-18-dependent manner. In wild-type Lm, the pore-forming toxin LLO allows the bacteria
to escape the phagosome and move to the cytosol, thus inducing rapid secretion of IL-12 and IL18 (80). CD8+ T cells are recruited to the red pulp after i.v. infection, localizing around large
numbers of Lm and nascently-infected monocytes and macrophages (81). In agreement with
previous work using i.v. Lm, several studies have indicated that the interferon gamma receptor
(IFNGR1), expressed on most myeloid cells and lymphocytes, is critical for immunity to Lm (82,
83) primarily because of its role in activating macrophages.

Tolerance and innate immunity in the liver
The liver is unique in that it receives both portal vein blood, carrying antigens derived
from the intestinal contents and microbiota, as well as oxygenated arterial blood. Its structure is
highly conducive to filtration and allows extremely large amounts of blood flow; however,
inflammation in the organ is tightly regulated so as to prevent inappropriate reactions to
nonpathogenic food-derived antigens (84). Blood flow slows in the liver due to the narrow,
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honeycomb-like sinusoids, allowing extensive contact between antigens, as well as circulating T
cells, with the phagocytes and antigen-presenting cells of the liver (84, 85).
Although not tightly bound like other endothelial layers, liver sinusoidal endothelial cells
(LSEC) physically separate the sinusoidal blood from the hepatocyte plates, forming a fenestrated
layer, under which is known as the space of Disse. LSEC, which make up nearly 50% of the nonparenchymal cells of the liver, play a central role in hepatic tolerance. These cells express several
Toll-like receptors, scavenger receptors, MHC I and II, costimulatory molecules CD80 and 86,
and lymphocyte adhesion molecules (86).

Internalized antigen cross-presented on MHC I

induces antigen-specific T cell tolerance, of high importance because the liver contains a larger
concentration of T cells than even lymphoid organs. Antigens can also be transcytosed and
released into the space of Disse, exposing hepatocytes to antigen too large to pass through the
fenestrated endothelium. Furthermore, T cell recognition of antigen presented on MHC I results
in a reciprocal signal that induces upregulation of PD-L1 on LSEC. Thus, CD8 T cells rapidly
proliferate but do not secrete IFNγ and are tolerized.
Kupffer cells (KC), the liver’s resident macrophages, exist in the sinusoidal lumen and
comprise approximately 35% of the steady-state non-parenchymal cells of the liver (86). These
cells secrete IL-10 and prostaglandins, suppressing antigen-specific T cell activation, but are
required for clearance of even low doses of Lm (85, 86). KC are not a homogenous population of
cells, and opinions differ on both their lifespan and whether they are bone marrow-monocyte
derived or are repopulated by hepatic stem cells. KC express high levels of complement receptor
CR-1 and capture C3b-coated bacteria under flow conditions, but they do not always internalize
captured bacteria. Gregory et al. showed that while critical for immunity to Lm, KC did not
internalize this bacterium. Instead, Lm remained bound extracellularly and PMN were recruited
to the site, killing the bacteria (63).
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1.6 PMN and their role in hepatic listeriosis
The fenestrated endothelium of the liver sinusoids and expression of hyaluronan on
sinusoidal endothelial cells allows PMN to enter the liver via CD44-hyaluronan interaction,
which can further be augmented during bacterial inflammation by production of serum-derived
hyaluronan associated protein (87). Gregory et al. found a 7-fold increase in liver PMN between
10 min and 6 hours after i.v. injection of Lm, which corresponded with a 10-fold reduction in
CFU over the same time-period (63). This demonstrated that upon acute insult, PMN could be
recruited rapidly to the liver, overcoming the tolerogenic environmental cues. Senescent PMN
taken up by KC have also been paradoxically suggested to suppress release of cytokines and
chemokines by KC (88).
Direct killing by PMN plays a primary role in hepatic clearance of Lm. PMN in the liver
could either kill bacteria released from apoptotic hepatocytes or may directly lyse infected
hepatocytes, releasing the bacteria from a protective niche and allowing killing (62, 89, 90).
Neutrophil extracellular traps (NETs) in the liver have also been demonstrated to enhance
bacterial capture by KC (86). Carr et al. also demonstrated that PMN were a major contributor to
TNFα production in the liver (91).

TNFα was previously shown to directly lyse infected

hepatocytes (92), and another study correlated hepatocyte lysis with PMN being in close
proximity (93). While the growth of Lm itself is also thought to lyse infected hepatocytes (90),
these results are suggestive that TNFα-mediated lysis of infected hepatocytes is a critical role of
PMN.

Depletion studies
Early work to determine the role of PMN in murine listeriosis relied on antibodymediated depletion using a clone (RB6-8C5) that was subsequently shown to bind both PMN and
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monocytes (94-98).

More recent depletion strategies designed to avoid this issue yielded

conflicting results about the importance of PMN for clearance from the liver (91, 99). Carr et al.
demonstrated that specific depletion of hepatic PMN beginning one day prior to infection yielded
more pronounced susceptibility in the liver than the spleen (91). This supported previous studies
which showed an increase in CFU in the liver, but not the spleen, at one day after i.v. infection of
RB6-8C5-depleted mice (94). Shi et al. found that PMN localized around foci of infection in the
liver, but that their specific depletion, beginning immediately post-infection, did not negatively
impact survival (99). The major difference in these studies appears to be the timing of PMN
depletion; removal of PMN after the infection by Shi et al. could plausibly have allowed PMN to
begin killing Lm before the effects of the antibody became apparent.

PMN recruitment to the infected liver
Ly6G+ PMN make up less than 1% of the total steady state non-parenchymal cell
population of the liver (63, 88); however, PMN rapidly increase following infection and PMNrich hepatic abscesses have been observed in both BALB/c and B6 mice after i.v. infection (53,
99). PMN develop in the bone marrow and are retained by interaction of CXCR4 with CXCL12
(SDF-1α) and the integrin VLA-4 with endothelial cell VCAM-1, remaining in the marrow for up
to two days after full maturation (87, 100, 101). During inflammation, a variety of chemotactic
factors including leukotriene B4 (LTB4), C5a, IL-8 (CXCL-8 in mice), CXCL1, and CXCL2,
may stimulate PMN egress to the blood (100, 102). Hepatic PMN recruitment after i.v. Lm
infection is sustained by the IL-23/IL-17 axis (103). After infection, IL-17A is produced by the
γδ T cell population of the liver (104) and influences several cytokines and chemokines that
impact PMN recruitment, including IL-6, G-CSF, and GM-CSF (103, 104). IL-23 is an IL-12
family member previously demonstrated to maintain IL-17-producing cells and play a PMNdependent protective role in several other infection models (103, 105). Meeks et al. found that
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IL-23 was required for protection against i.v. Lm, but that its effects were only apparent after
several days of infection, indicating that redundant factors played a role in early PMN recruitment
to the liver (103).
Leukotriene B4 (LTB4), a lipid derived from arachidonic acid, is a powerful chemotactic
signal for PMN (106, 107). Upon initial PMN encounter with apoptotic cells or bacteria, it is
secreted by the PMN themselves. It then serves as a signal relay molecule, creating a PMN
swarm that is sustained until factors produced within the swarm initiate its dispersal (108, 109).
Formylated peptide receptors (FPR) also play a local role in PMN recruitment within the infected
tissue. Mice lacking FPR were significantly more susceptible to i.v. Lm infection than wild type
controls when CFU were assessed at 2 dpi (110-112). PMN were still found in the livers of these
mice, however, again suggesting that redundancy amongst chemotactic factors was important for
PMN migration into the liver, but that other factors could play very specific, non-overlapping
roles in recruitment to foci of Lm infection.

Use of human vs. murine PMN
Significant differences in mouse and human physiology have historically presented some
barriers to the experimental use of mouse PMN. Although many of these differences can easily be
overcome, perception has led to human peripheral blood PMN being used even in studies where
the question primarily relates to a mouse phenotype, such as susceptibility to bacterial disease.
As the largest population of cells in human blood, PMN are easily obtained from a peripheral
blood sample. In contrast, they only account for about 15% of circulating immune cells in the
mouse (102, 113). Mouse bone marrow, however, is an abundant source of morphologically
mature PMN that release both primary and secondary granules and are suitable for functional
assays including adoptive transfer (114, 115). Murine PMN do possess some functional
differences compared to human PMN; they lack defensins and respond poorly to the formylated
18

peptide fMLF, although they do possess a strong affinity for penta- and tetra-formylated peptides
from Lm and Staphylococcus aureus (110, 112, 116). Murine PMN have also been shown to
migrate more slowly than human blood PMN in chemotaxis assays (117, 118).

1.7

Type I Interferons

Receptor and signaling
Type I IFNs (IFNα/β) are multifunctional cytokines with both pro- and anti-inflammatory
roles in immunity. The role of these substances in the progression or control of listeriosis is thus
complex and most studies have failed to appreciate that the way in which infection is performed
may complicate the final result. They were first characterized over sixty years ago as substances
that could “interfere” in viral infections (119). Over a dozen IFNα subtypes as well as a single
IFNβ subtype have been identified, and all of these bind the common type I IFN receptor
(IFNAR), a heterodimer composed of IFNAR1 and IFNAR2 (120, 121) (Fig. 1.2).

The

predominant signaling pathway activated by ligation of IFNAR involves activation of tyrosine
kinases JAK1 and TYK2, which in turn phosphorylate STAT1 and STAT2.

Once

phosphorylated, STAT1 and STAT2 bind interferon response factor (IRF) 9 and translocate to the
nucleus, where they bind interferon stimulated response elements in DNA to stimulate
transcription. Several other STATs, mitogen activated protein kinases (MAPK) and p38, and
PI3K are also activated by ligation of IFNAR (120, 121). IFNAR1 is expressed on all nucleated
cells and binds IFNβ with a higher affinity than any of the IFNα subtypes, and strong similarities
in expression have been shown between human and mouse cells (122).
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Expression and secretion
Secretion of type I IFN is induced by ligation of Toll-like receptors (TLR) and cytosolic
sensors such as DDX41 and stimulator of interferon genes (STING) (123, 124). Cytosolic
DDX41 senses production of the bacterial second-messengers cyclic di-AMP and GMP, acting as
a pattern-recognition receptor. STING is embedded in the endoplasmic reticulum and can act as
an adaptor protein for DDX41 but also can directly sense cytosolic dinucleotides as well as DNA
and RNA. In Lm, cyclic-di-GMP is secreted through multi-drug resistance pumps (125); strains
that overexpress MDR-T have been characterized as hyper-inducers of IFNβ (126). Mice in
which STING has been knocked out produced significantly less type I IFN in response to Lm
infection than wild type mice; however, this did not affect susceptibility measured by CFU in the
spleen (127).
During viral infection, type I IFNs are secreted by plasmacytoid dendritic cells (pDC)
after stimulation of endosomal TLR7 and TLR9 together with the MyD88 adaptor (128).
Stockinger et al. sorted spleen cells to determine that macrophages produce type I IFN 24h after
intraperitoneal (i.p.) Lm infection (129). Another study determined that a subtype of TNF and
iNOS-producing dendritic cells (Tip-DC) made IFNβ in the spleen after i.v. and i.p. Lm infection
(130).

Influence on immunity to viral challenge
Mice lacking the common type I IFN receptor (IFNAR1-/-) were found to be highly
susceptible to even low-titer challenge with vesicular stomatitis virus, Semliki Forest virus, and
vaccinia virus, thus demonstrating that IFNα/β signaling was essential for immunity to acute viral
infection (131). Type I IFN can prevent or restrict viral replication through a variety of means,
such as induction of cyclin-dependent kinase inhibitors, upregulation of apoptosis promoters
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TRAIL and FAS/FASL, and increasing expression of Mx-1, a GTPase which blocks viral
transcription through interactions with viral proteins (132, 133). These cytokines also have
diverse pro-inflammatory effects on the host, such as stimulation of dendritic cell maturation;
upregulation of MHC-I, MHC-II and costimulatory molecules CD80 and CD86; and increasing
secretion of antibodies from B cells (134, 135). It is somewhat unexpected, therefore, that a
robust type I IFN response may also promote more severe disease during influenza virus infection
(136, 137).
Influence on susceptibility to bacterial challenge
The role of type I IFN in the response to bacterial challenge is likely to be considerably
more complex than what has been observed in viral infections. Type I IFN signaling improved
disease resistance in mice infected with extracellular encapsulated bacteria Group B streptococci,
Streptococcus pneumoniae, and E. coli (138). In fact, mice deficient for IFNα/β or IFNAR1 were
hyper-susceptible to these bacteria, thought to be due to a failure of macrophages to produce
TNFα and IFNγ (138). This same study also suggested that in the case of these bacteria, IFNα/β
and IFNγ synergized for bacterial clearance.
In contrast, the presence of type I IFNs during infection with intracellular bacterial
pathogens such as Mycobacterium tuberculosis (139, 140), Francisella tularensis (105),
Salmonella enterica (141), and Lm (142-145) has been generally shown to be detrimental to the
host. Like the initial viral studies, studies using IFNAR1-/- mice suggested that IFNα/β signaling
modulates multiple facets of innate immunity to bacteria. Down-regulation of IFNGR1, which
inhibits macrophage responsiveness to IFNγ, was found to be a major consequence of Lm
infection (82, 83, 146). Type I IFN also was shown to cause mass apoptosis of splenic T cells by
sensitizing the cells to Listeria-induced apoptotic signals (144). In models of both Francisella
tularensis and i.v. Lm infection, IFNAR1-/- mice recruited more PMN to the spleen (105, 147).
Another study using i.v. Lm infection found more robust recruitment to TNFα-producing CD11b+
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cells to the spleens of Lm-infected IFNAR1-/- mice (142). In all of these examples, a lack of type
I IFN signaling resulted in improved bacterial clearance in comparison to wild type mice.

1.8

Prostaglandin E2
Prostaglandin E2 (PGE2) is a lipid derived enzymatically from arachidonic acid present

in the cell membrane. It is a member of a family of signaling lipids called eicosanoids which
encompasses leukotriene B4 (LTB4), thromboxane A4, and prostacyclins. Although well-known
as a pro-inflammatory mediator, PGE2 and the pathways that cause its induction have also been
widely studied for their role in aberrant polarization of T cell responses and inhibition of
macrophage function (148-151). The role of PGE2 in the body seems to depend strongly on the
tissue, the stimulus causing its induction, and the timing of secretion. For example, PGE2 plays a
homeostatic role in maintenance of barrier integrity of the gastric mucosa (152), but is also made
in response to commensal bacteria and limited PMN activation in response to acute mucosal
infection with Toxoplasma gondii (153). PGE2 plays a maintenance role in normal kidney
function and blood pressure (152), but it has also been shown to drive IL-10 secretion in the liver
after infection or inflammatory stimulus (154, 155). Suppression of innate immunity by PGE2
may outweigh its induction of pro-inflammatory pathways in many situations.
Production
PGE2 secretion can be stimulated by mechanical trauma and inflammatory stimuli
including bacteria (156). It is derived from a series of enzymatic reactions (depicted in Fig. 1.3)
beginning with release of arachidonic acid from the cell membrane by one of three phospholipase
A2 enzymes, a calcium-dependent cytosolic PLA2 (cPLA2), a secreted pLA2 (sPLA2), and a
calcium-independent pLA2 (iPLA2). cPLA2 and sPLA2 are inducible and activated by microbial
components, including secretion of LLO, which causes an intracellular calcium flux (157). Once
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arachidonic acid is liberated, it may be oxidized by the cyclooxygenase enzymes (COX-1 and
COX-2) or by lipoxygenase. COX modification produces an intermediate product that is further
enzymatically modified by prostaglandin E synthase (PGES) to produce PGE2. Three isoforms
of PGES exist- microsomal PGES (mPGES) 1 and 2 and cytosolic PGES (cPGES).

A study

using peritoneal macrophages of BALB/c and B6 mice found that BALB/c macrophages express
higher levels of mPGES and thus produce more PGE2 when stimulated with LPS (150). Since
the discovery of the two isoforms in the 1990s, COX-1 has been considered the “housekeeping”
COX and COX-2 the inducible isoform.

Some studies have contradicted this convention,

however, and shown that both isoforms are present at homeostasis and induced by inflammation
(158).

If free arachidonic acid is metabolized by 5-lipoxygenase, this ultimately results in

leukotrienes including LTB4, a lipid with chemotactic properties for PMN (106, 107). Activation
of the 15-lipoxygenase pathway results in secretion of lipoxin A4 (LXA4), a pro-resolution lipid
produced during the plateau phase of PMN swarming (109, 159, 160). Using human PMN, Levy
et al. showed that PGE2 exposure switched lipoxygenase activity from predominately 5lipoxygenase, producing LTB4, to 15-lipoxygenase, making LXA4, within 5 hours (160). This
study provided strong evidence that PGE2 could induce downregulation of the PMN immune
response.

Receptors and signaling
PGE2 can be produced by most nucleated cells, with the notable exception of B
lymphocytes, and is secreted to the extracellular environment by multidrug resistance transporter
4 (156, 161, 162). It is rapidly removed from circulation, making serum measurements difficult,
and may also be degraded by a dehydrogenase, forming inactive 15-keto PGE2, or albumin,
forming 15-keto PGA2 and PGB2 (162-165). In general, PGE2 acts locally, with autocrine and
paracrine functions noted in many cell types (156). PGE2 binds four G-protein coupled receptors
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expressed on a variety of tissues and cells (EP1-EP4) (Fig. 1.4) (152, 166, 167). EP2 and EP4 are
coupled to Gαs in the cytoplasm and stimulate an increase in cyclic adenosine monophosphate
(cAMP) through activation of adenylate cyclase (168). EP4 can also stimulate a PI3K-dependent
ERK1/2 pathway and both EP2 and EP4 have been shown to activate GS3K/β catenin signaling,
demonstrating potential roles in the pathogenesis of certain cancers (162). Although EP4 has a
higher affinity for PGE2 than EP2, stimulation of EP2 stably transfected in HEK cells resulted in
accumulation of more cAMP, speculated to be a result of faster desensitization of EP4 due to
receptor internalization (168, 169). Conversely, EP1 and EP3 stimulation results in a decrease in
cAMP and an increase in intracellular calcium (170). Dendritic cells were shown to express all
four EP receptor subtypes, while mouse peritoneal PMN were found to express EP2 and EP4, but
not EP1 and EP3 (171).

T and B cells also express PGE2 receptors, with both immune

stimulatory and inhibitory effects reported depending on cellular context (152, 172).

Pro-inflammatory roles of PGE2
PGE2 is involved in the classic symptoms of inflammation- warmth, redness, and fever,
through its roles in vasodilation and lymphocyte recruitment and induction of IL-6 (173, 174). It
is considered a strong pro-inflammatory mediator, and as such has quite a number of drugs
directed at it. Non-steroidal anti-inflammatory drugs (NSAIDS) such as ibuprofen broadly target
all prostaglandin production through suppression of both COX-1 and COX-2, thus leading to
some of their negative side effects such as gastrointestinal bleeding (152). COX-2 specific drugs
such as celecoxib, on the other hand, target the inflammatory induction of only COX-2 and have
fewer side effects (152). For the purposes of this document, however, the focus will be on the
anti-inflammatory effects of PGE2.
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Anti-inflammatory or immunosuppressive roles of PGE2
Numerous studies have examined the effect of PGE2 on both T cell responses and
phagocyte functions and concluded that it is an immunosuppressive compound with a role in
Th1/Th2 polarization. PGE2 was shown to suppress IFNγ and IL-2 from Th1 clones, induce
FOXP3 expression, and prevent anti-CD3-induced proliferation (148, 175).

Recently, outer

membrane vesicles released by Helicobacter pylori were shown to induce COX-2 expression and
robust PGE2 secretion in human peripheral blood monocytes. In turn, this strongly inhibited T
cell proliferation without stimulating apoptosis (176). Hutchison and Myers identified PGE2 in
splenocyte culture supernatants as a factor that suppressed peritoneal macrophage phagocytosis of
Lm (177). Using splenocytes stimulated with S. aureus Cowan 1, Kuroda et al. found that PGE2
strongly suppressed Th1 activation and IFNγ secretion, but that PGE2 secretion in response to in
vitro stimulation was not significantly different amongst different mouse strains. From these
results, they concluded that BALB/c cells were in fact more sensitive to the effects of PGE2 and
that this sensitivity played a pivotal role in Th2 polarization in BALB/c mice (149). Later, the
same group found that LPS or S. aureus-stimulated BALB/c macrophages produced more PGE2
than B6 macrophages, and that this PGE2 suppressed Th1 activation in an EP-4 dependent and
self-regulatory manner (150).

Thus, PGE2 modulates aberrant Th2 activation in BALB/c

myeloid cells in vitro through both differential production and increased sensitivity compared to
B6 cells.
EP2 and EP4-mediated accumulation of intracellular cAMP is thought to result in some
of the immunosuppressive effects of PGE2 (151, 152, 171, 178-180).

In Histoplasma

capsulatum-infected macrophages, ligation of EP2 and EP4 resulted in lower levels of
phagocytosis, decreased phosphorylation of NFκB, and lower secretion of TNFα (178).

In

alveolar macrophages, EP2 and EP4 ligation inhibited phagocytosis of Klebsiella pneumoniae in
a cAMP-dependent manner and inhibited killing through effects on NADPH oxidase (151, 179).
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In activated dendritic cells, PGE2 or EP4 agonism resulted in lower secretion of proinflammatory chemokines, but also upregulated receptors necessary for migration to lymph nodes
(152). Also somewhat contradictory, PGE2 treatment of mouse peritoneal PMN resulted in
accumulation of cAMP and lower TNFα secretion than control cells but enhanced IL-6
production when the cells were also treated with LPS (171). This result was suggested to be
caused by differential signaling of EP2 and EP4.
Monocytes and PMN are rapidly recruited to sites of infection, including the intestinal
lamina propria, mesenteric lymph nodes, the spleen, and the liver (75, 147). Although many cells
secrete PGE2, Grainger et al. recently showed that monocytes recruited to the murine intestinal
lamina propria produced PGE2, thus modulating PMN function in response to T. gondii (153).
Application of PGE2 to human PMN was shown to inhibit superoxide production in a cAMP- and
EP2-dependent manner and inhibited chemotaxis to fMLP independent of cAMP accumulation
(180). It is largely unknown, however, how PGE2-dependent decrease in one or more killing
mechanisms might impact the overall ability of PMN to kill pathogenic bacteria.

1.9 Overall hypothesis
The release of cytokines, chemokines, and signaling lipids during natural infection with
foodborne pathogens is an understudied area of microbiology and immunology. The use of
intravenous and intragastric infection, while efficient and reproducible for the most part, has
hampered the synthesis of knowledge of how a relatively mild infection originating from the
gastrointestinal tract produces life-threatening disseminated infection in vulnerable populations.
In this study, foodborne transmission and in vitro infection were used to assess how two
mediators not classically thought of as part of bacterial infection, IFNα/β and PGE2, impact early
immunity to Lm. I hypothesized that IFNα/β, while clearly capable of modulating immune

26

responses, was induced as a result of the infection method and was specifically a consequence of
a very large number of bacteria initiating colonization of the spleen simultaneously.
Additionally, I hypothesized that foodborne infection triggered a condition in the livers of
susceptible BALB/c mice, namely overproduction of PGE2, which led to modulation of PMN
clearance of Lm. As predicted, results showed that foodborne infection elicited little production
of IFNα/β. Additionally, mice lacking the common type I IFN receptor were not more resistant to
foodborne Lm infection, a sharp contrast to the phenotype observed with these mice using i.v.
infection. These data suggested that most of the detrimental effects attributed to type I IFN
during listeriosis may actually be an artifact of the i.v. infection model.
Furthermore, results demonstrated that murine PMN efficiently kill serum-opsonized Lm
using both oxidative and non-oxidative mechanisms. This led to the conclusion that there were
no intrinsic differences in the capacity of PMN from susceptible BALB/c and resistant B6 mice to
kill Lm and suggested that if PMN in the BALB/c liver were deficient, they were responding to
the hepatic microenvironment. Accordingly, more PGE2 was found in cells removed from
infected BALB/c livers.

When exogenous PGE2 was applied to bone marrow PMN, it

significantly decreased their killing efficiency, thus suggesting that overproduction of PGE2
under infection conditions could modulate the PMN response to Lm.
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Figure 1.1 Orally-acquired Lm must pass through sequential anatomical barriers and
bottlenecks to cause infection.
Up to 90% of an ingested Lm inoculum is either killed in the stomach or shed in feces within a
few hours (35, 71). Lm that survive must compete with the gut microbiota to gain access to the
epithelium (181, 182); it has been estimated that invasion of the mucosal barrier is a rare event,
with only 1 in 106 bacteria reaching the underlying lamina propria (72). If i.g. inoculation is used,
or if an overwhelmingly large dose (≥109 CFU) is used with any oral infection method, rapid
dissemination to the liver, presumably via the portal vein, is observed. Lm not transported
through portal circulation must disseminate to the mesenteric lymph nodes (MLN), avoid killing
by activated phagocytes, and then gain access to the blood circulation. Given the number of
barriers faced, it is likely that small numbers of Lm reach the spleen and liver asynchronously. In
contrast, Lm that are i.v. injected seed the spleen and liver as a large bolus within 10-15 minutes
after administration (63, 64, 183).
This figure was published as part of reference (184) (Pitts, et al. 2018). DOI:
10.3390/pathogens7010013
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Figure 1.2 Model of type I interferon signaling
For type I IFN signaling to occur, IFNα or IFNβ must bind IFNAR1, which then recruits IFNAR2
to form a heterodimer. These two extracellular-facing proteins are coupled to Tyk2 and Jak1 in
the cytoplasm, which phosphorylate Stat1 and Stat2, causing them to dimerize, bind interferon
response factor (IRF9), and then translocate into the nucleus. Once in the nucleus, an interferon
response element (ISRE) is bound on DNA, causing transcription.
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Figure 1.3 Scheme of eicosanoid production
Arachidonic acid is released from membrane phospoholipids by activated by phospholipase A2
(PLA2). If acted upon by cyclooxygenase enzymes (COX1/2), an intermediate prostaglandin is
produced that may then be further modified by tissue or cell-specific synthases such as
microsomal PGE synthase (mPGES). If arachidonic acid is acted upon by the lipoxygenase
enzymes (5-LOX and 15-LOX), leukotriene B4 (LTB4) and lipoxin A4 (LXA4) are produced.
PGE2 exposure in PMN may also trigger a switch from 5-LOX to 15-LOX, inducing secretion of
pro-resolving LXA4 (160). Non-steroidal anti-inflammatory drugs (NSAIDS) act on the COX1
and COX2 enzymes. The intermediate PGH2 may also be acted on by other specific synthases to
produce other eicosanoid family members, including prostacyclin, thromboxane (TXA2), and
prostaglandin D2 (PGD2)
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Figure 1.4 PGE2 receptors
PGE2 binds four 7-transmembrane spanning G-protein coupled receptors (EP1-EP4). EP2 and
EP4 stimulate adenylate cyclase (AC), causing an accumulation of intracellular cyclic adenosine
monophosphate (cAMP) and activation of protein kinase A (PKA). One of the downstream
consequences of this pathway is transcription of COX-2, stimulating a positive feedback loop
(168). Ligation of EP4 can also stimulated PI3 kinase (PI3K), causing downstream transcription
of PGE synthase, also feeding into the positive feedback loop.

Ligation of EP1 causes

intracellular calcium flux and activation of protein kinase C (PKC) and can also directly block
activation of AC, and EP3 ligation also directly blocks AC activation.

ERK, extracellular

signaling related kinase; EGR1, early growth response factor 1, PLC, phospholipase C; DAG,
diacylglycerol; IP3, inositoltriphosphate
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2. Materials and Methods
Bacteria
Mouse-adapted (inlAm-expressing) L. monocytogenes (Lm) EGDe derivatives SD2000, SD2001
(kanamycin-resistant) and SD2710 (constitutive GFP) were used in these studies (61, 75).
Lm EGDe and an isogenic inlA deletion (ΔinlA) mutant were provided by Cormac Gahan
(University College Cork, Ireland). Expression of the modified inlAm surface protein allows the
bacteria to efficiently bind murine E-cadherin, promoting invasion of the intestinal epithelium
(58). Lm SD2000 was created by integrating inlAm into the chromosome of Lm ΔinlA as
described by Jones et al. (75). Kanamycin (50 μg/mL) was added to plates for selection of Lm;
IPTG (isopropyl-β-D-thiogalactopyranoside; final concentration, 1 mM) was added to induce the
expression of antibiotic resistance genes carried on pIMC3 derivatives.
Media
RP-5- medium was comprised of RPMI 1640 [Life Technologies # 21870], 5% FBS [Gemini],
2.5 mM L-glutamine, 10 mM HEPES, 0.1 mM β2-mercaptoethanol [Sigma-Aldrich]. RP-10medium was identical to RP-5 except with the addition of 10% FBS. For bone marrow, RP-10was supplemented with 2 mM EDTA and 25 μg/mL gentamicin [Gibco]. RP10+ contained
100U/mL penicillin and 0.1 mg/mL streptomycin [Sigma]. Flow cytometry buffer contained
Ca2+/Mg2+-free HBSS, 25mM HEPES, 5mM EDTA, 1% FBS. Cells were sorted into a 1:1
mixture of buffer and sterile FBS with the addition of 25 μg/mL gentamicin.
Mice
BALBcBy/J (BALB/c; stock # 001026), C57BL/6J (B6; stock # 000664), and B6.129SCybbtm1Din/J (gp91phox-/-; stock # 002365), and IFNγ-/- (stock #002287) mice were purchased from
The Jackson Laboratory (Bar Harbor, ME) and housed in a specific pathogen-free facility. The
IFNγ-/- mice were crossed with Thy1.1/luciferase-expressing C57BL/6 mice (185) (originally
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obtained from Dr. Robert Negrin, Stanford University) to obtain homozygous Thy1.1+/+IFNγ-/progeny. IFNAR1-/- mice were obtained from Dr. Jayakrishna Ambati (University of Kentucky).
Both male and female animals were used in all experiments. Bone marrow was harvested from
animals 8-16 weeks old; no significant differences were noted in PMN recovery per gram of
weight between male and female mice. Animals used for in vivo infection were 6-12 weeks old at
time of infection. Mice were euthanized by cervical dislocation. Blood was collected from the
aorta immediately after euthanasia and transferred to a serum separator tube (BD), followed by
centrifugation for 2 min at 20,000 x g. Serum was stored at 4°C for use the same day or at -80°C
for later use. To pre-treat bacteria with serum, autologous mouse serum was added to Lm (10%
final concentration) and the mixture was incubated at 37°C for 30 min. Pre-treatment with serum
alone in the absence of PMN had no effect on Lm growth (data not shown). Serum was heatinactivated by incubating at 55°C for 30 min. All procedures were approved by the Institutional
Animal Care and Use Committee at the University of Kentucky.
In vivo infection
For in vivo infection, intestinally passaged Lm were grown to early stationary phase in Brain
Heart Infusion (BHI) broth (Difco) shaking at 37° C (for i.v. infection) or standing at 30° C (for
foodborne infection) and then aliquots were prepared and frozen at -80° C until use as described
previously (186). An aliquot was thawed on ice and cultured for 1.5 h in BHI broth shaking at
37° C (i.v.) or standing at 30° C (foodborne).

For i.v. infection, Lm were washed once,

suspended in sterile PBS, and diluted to the appropriate concentration. A total volume of 200 μL
was aseptically injected into the lateral tail vein. Uninfected mice received a 200 μL injection of
sterile PBS via the lateral tail vein.

For foodborne infection, Lm were washed twice and

suspended in 5 μL of a salted butter (Kroger) plus sterile PBS mixture (3:2 ratio) and then added
to a 2-3 mm piece of white bread (Kroger). Mice were fasted for 16-24 hours prior to ingestion
of the Lm-contaminated bread and housed on raised wire flooring as described previously (187,
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188). Uninfected mice were fasted and fed an uncontaminated piece of bread. For experiments
requiring only CFU determination, spleens and livers were harvested aseptically and
homogenized (Fisher PowerGen 1000, 60% power) in sterile water for 30 seconds. For all CFU
determination, dilutions were prepared in sterile water (chapter 3) or PBS (chapters 4 and 5) and
plated on BHI agar with or without Kanamycin and IPTG. Colonies were counted after 24 h
incubation at 37°C.
In vitro infection
For in vitro infection of PMN, a glycerol stock of each Lm type was struck out onto BHI agar
(Difco). After overnight growth, a freshly streaked colony was inoculated into BHI broth and
grown shaking at 37˚C overnight (16 h). Lm were washed once with Ca2+/Mg2+-free HBSS and
then diluted in the same buffer to the appropriate concentration for infection. For in vitro
infection followed by COX-2 analysis (Fig. 5.1), cells were exposed to Lm SD2000 (MOI =1).
25 μg/mL gentamicin was added after 2 hr and incubation was continued overnight.
Isolation of splenocytes
Spleens were injected with 100 U of type IV collagenase (Worthington) in a total volume of 1 mL
of HBSS. Spleens were minced, additional collagenase was added for a final concentration of
200 U/mL, and the samples were incubated for 30 min at 37°C in 7% CO2. The digested tissue
was pushed through a sterile screen (# 80 mesh), filtered, and red blood cells were lysed using an
ammonium chloride buffer. For some experiments in Chapter 3 requiring only a single cell
suspension, spleens were mechanically dissociated by pushing through mesh screens without
collagenase treatment using a 3-mL syringe plunger. For CFU determination, a portion of the
splenocyte single cell suspension was removed and diluted in sterile water prior to plating on BHI
agar.
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Liver non-parenchymal cell preparation
At indicated time points post-infection, mice were euthanized and livers were perfused via the
hepatic portal vein with 11 mL of collagenase type IV solution (250 U/mL in HBSS), removing
blood. The perfused tissue was cut into small pieces, transferred to a 50-mL tube containing
DNase (10 U/mL; Worthington) and collagenase type IV (100 U/ mL) in 10 mL of RP-5- and
incubated for 35 min shaking at 37°C. The digested tissue was gently pushed through a mesh
screen (no. 80 mesh) to create a single cell suspension. At this point, one tenth of the volume was
removed for determination of CFU burdens. Non-parenchymal cells were enriched by allowing 2
min settling time followed by centrifugation for 1 min at 50 x g at 4°C. Supernatant was
centrifuged at 300 x g at 4°C for 10 min, the pellet was suspended in 30 mL of RPMI 1640, and
the prior two steps were repeated. Finally, the pellet was suspended in 1.6 mL cold RPMI 1640
followed by addition of 2.4 mL cold 40% Histodenz (Sigma) in PBS. The suspension was
layered under 2 mL of cold RPMI 1640 in 15 mL polypropylene tubes that had been pre-coated
with FBS. Samples were centrifuged for 20 min at 4°C at 1500 x g with no brake. The interface
was collected and passed through a filter to remove clumps.
Type I IFN ELISA
For detection of type I IFN, lymphocytes were depleted from splenocyte suspensions using APCconjugated anti-B220 (RA3-6B2) and anti-TCRβ (H57-597) antibodies (eBioscience) and IMag
anti-APC magnetic beads (BD Biosciences).

This protocol resulted in greater than 90%

depletion of both B cells and T cells for all samples. APC-enriched splenocytes were cultured for
24 h at 37° C in 7% CO2 at a density of 1.0 x 106 cells/200 μL in 96-well flat bottom plates in
RP10- containing 12.5 μg/mL gentamicin. Cultured cells were centrifuged at 300 x g for 8
minutes and the supernatants were harvested and stored at -80° C. Cytokine concentrations were
determined using the Verikine Mouse IFNβ ELISA kit (PBL Assay Science, Piscataway, NJ) and
the Mouse IFNα Platinum ELISA kit (eBioscience).
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IL-10 ELISA
For IL-10 detection, spleens were harvested aseptically and placed into 2 mL of ice-cold PBS,
homogenized for 30 seconds (Fisher PowerGen 1000, 60% power), split into aliquots, and stored
at -80° C. An aliquot was thawed on ice and centrifuged at 14,000 x g for 10 min, and the
supernatant was collected. ELISA was performed using anti-mouse IL-10 capture antibody
(JES5-16E3), biotin-conjugated anti-mouse IL-10 detection antibody (JES5-2A5), and mouse IL10 standard (eBioscience).
PGE2 EIA
Prostaglandin E2 was measured using the Prostaglandin E2 Metabolite (PGEM) EIA kit (Cayman
Chemical No. 514531) according to manufacturer instructions. Liver non-parenchymal cells
were gradient-enriched and cultured overnight at a density of 2.5 x 105 cells per well in a final
volume of 0.5 mL in 24-well low adherence dishes (Corning). Cells and supernatant from like
samples were pooled, and proteins were precipitated using four volumes of ice-cold acetone
followed by incubation at -20˚C for at least 2 hr. Samples were dried under nitrogen and
suspended in the kit buffer according to instructions. Lipids were extracted using ethyl acetate
according to the protocol supplied in the PGEM assay kit and samples were suspended in the kit
assay buffer.
Bone marrow derived monocytes
BALB/c mice were euthanized and femurs and tibias were removed and flushed with 10 mL RP10+. Red blood cells were lysed by exposure to an ammonium chloride buffer and remaining
cells were washed and counted. Cells were plated at 1 x 106 cells/mL in 16 mL in ultra-low
attachment plates (Corning No. 3262) and m-CSF was added to each plate at a final concentration
of 20 ng/mL. Cells were harvested on day 4 or day 5, washed with RP-10-, and plated in lowadherence 24 well plates (Corning No. 3473) at 2.5 x 105 cells/mL in 1 mL RP-10-.
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Flow cytometry
Cells were stained using fluorescently-conjugated antibodies specific for the following molecules:
CD64 (X-54-517.1), Ly6C (HK1.4), and Ly6G (1A-8), purchased from Biolegend; F4/80 (BM8),
CD11c (HL3), CD11b (M1/70), CD19 (D3), B220 (RA3-6B2), CD3 (17A2), and streptavidin,
purchased from eBioscience. Biotin-conjugated IFNGR1/CD119 (2E2; Biolegend) was detected
with PE Cy5-conjugated streptavidin (eBioscience). Intracellular COX-2 was detected after
incubation with fixation and permeabilization buffer (BD) according to manufacturer instructions
using FITC-conjugated anti-COX-2 antibody purchased from Cayman Chemical. Dendritic cells
were defined as CD11chiF4/80-/lo, macrophages as CD11c-/lo and F4/80hi or CD64hi; B cells as
CD3-B220+CD19+ or Ly6G-Ly6C-CD19+, T cells as CD3+CD19- or B220-CD3+TCRβ+; PMN as
Ly6GhiLy6CintCD11b+ or Ly6GhiLy6C+/-, monocytes as Ly6G-Ly6Chi, and B cells as Ly6G- Ly6CCD19+. Fluorescence was measured using an LSR II flow cytometer (BD Biosciences) or an iCyt
Synergy sorter and analysis was performed using FlowJo v.10 (Tree Star). The sort gating
strategy incorporated live cell and singlet gates prior to gating on individual markers; sort purities
for PMN ranged from 92-99%. Following collection, cells were washed twice with RP-10- prior
to use.
Bone marrow harvest for PMN enrichment
Marrow was flushed from femurs and tibias with RP10- supplemented with EDTA and 25 μg/mL
gentamicin. Cells (two bones per tube) were passed through a sterile mesh filter into a 15 mL
polyethylene terephthalate (PET) tubes (Corning) and pelleted by centrifugation at 400 x g.
Erythrocytes were lysed by exposure to 0.2% NaCl for 20 sec followed by addition of an equal
volume 1.6% NaCl.
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Density gradient enrichment of PMN
Following erythrocyte lysis, PMN were enriched as described previously (115). Briefly, 3 mL
Histopaque 1077 was gently layered onto 3 mL Histopaque 1119 in a 15 mL PET tube. Cells
were resuspended in cold PBS at 8-12 x 106 cells/mL and overlayered on the Histopaque
suspension at 8-12 x 106 cells per tube. Tubes were centrifuged according to author’s instructions
and the bottom layer of cells was recovered and suspended in RP-10- or flow cytometry buffer.
In vitro killing assay
PMN (105/well) were plated in 96-well flat-bottom tissue culture-treated plates in 100 μL in RP10 and incubated at 37°C in 7% CO2 for 1 hour to allow a period of recovery. Lm was added at
the indicated MOI in a volume of 20-40μL to 3-6 wells per sample group. In each experiment, a
group of wells contained bacteria only (no PMN) to assess growth/survival. The plate was
centrifuged at 300 x g for 5 min and then incubated at 37˚C in 7% CO2. At each time point, the
contents of each well was transferred to an individual microcentrifuge tube and wells were
vigorously washed 3x with PBS and examined microscopically to ensure that all cells were
removed. Serial dilutions of each well were prepared in PBS and plated on BHI agar. The
percentage of Lm killed was calculated by dividing the number of CFU from wells with PMN by
the mean number of CFU from wells without PMN.
Gentamicin protection assay
Gradient-enriched PMN were plated and exposed to serum-opsonized Lm as described above.
Gentamicin was added at a final concentration of 10 μg/ml at 10 minutes post infection (mpi). At
indicated time points, the cells were washed once with RP-10-, lysed by addition of sterile water,
and plated on BHI agar.
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Chemotaxis assay
An under-agarose assay was used as described previously by Heit and Kubes (118), with the
exception of the following modifications. Ultra-pure agarose (1%; Invitrogen) was dissolved in
Ca2+/Mg2+-free HBSS and diluted with phenol red-free RPMI 1640 containing a final
concentration of 2.5% FBS. FBS-coated 60 mm petri dishes were filled with 4.5 ml of the agarose
mixture. 3 mm holes were cored 1 or 2 mm apart (indicated in figure legend) using a sterilized
template made from a silicone sheet and a hollow punch tool. Either 1 μM formylated synthetic
peptide (fMIVTLF plus fMIGWII; Bio-Synthesis, Inc.) or 100 nM leukotriene B4 (Cayman
Chemical No. 20110) diluted in Ca2+/Mg2+-free HBSS was applied to the center well and allowed
to diffuse into the agarose for 20 min prior to application of gradient-enriched PMN (1 x
105/well) to the outer wells. Dishes were incubated at 37°C in 7% CO2 for 3 h. Images were
acquired in DIC mode with a Nikon A1R confocal microscope, using a 10x air objective with a
numerical aperture of 0.45 and the transmitted light detector. Image size was 4096 by 4096 pixels
with a resolution of 0.31 micrometer/pixel. Distance traveled was determined using the manual
measurement tool in the NIS-Elements software program (Nikon).
Immunofluorescent microscopy
Sorted PMN were plated in RP-10-, rested for 1 hr, and then Cytochalasin D [Sigma] (20 μM in
DMSO) was added and cells incubated at 37°C in 7% CO2. Lm SD2710 was added to the wells
and the plate was centrifuged for 5 min at 300 x g followed by incubation for 5 min at 37°C in 7%
CO2. Difco Listeria O Antiserum Poly [BD Biosciences] and goat anti-rabbit IgG–Texas Red
(Thermo Fisher) were used to perform differential “in/out” staining as described previously (75).
Cells were visualized using a Zeiss Axio Imager.Z1 with a 100x/1.4 NA PlanApo oil immersion
objective and analyzed with AxioVision software. Slides were blinded and examined by two
different investigators; average values are reported.
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Reactive oxygen species
Gradient-enriched PMN were plated in RP-10-, rested for 1 hr, and then centrifuged at 300 x g
and suspended in Ca2+/Mg2+-free HBSS. Dihydrorhodamine 123 (DHR, Cayman Chemical No.
85100) suspended in DMSO and diluted in HBSS was added to wells (final conc. 2.5 μg/mL) 15
min prior to addition of either Lm or 20 nM PMA diluted in HBSS (Sigma No. P1585). Plates
were centrifuged at 300 x g for 5 min and then incubated at 37°C in 7% CO2. To scavenge
reactive oxygen intermediates, cells were incubated for 90 min with 50 mM 4-hydroxy Tempo
dissolved in HBSS [Tempol, Sigma No. 176141]. Lm was added at the indicated MOI and
further incubated for 30 min. DHR was added during the final 15 min of incubation. In both
cases, DHR fluorescence was analyzed by flow cytometry in the FL-1 channel after fixation using
1% paraformaldehyde.
Serine protease inhibition
Cells were treated with diisopropylfluorphosphate (DFP; Sigma No. D0879) suspended in
isopropanol and diluted in HBSS for 30 min at 37°C in 7% CO2. DHR was added to the wells
prior to addition of Lm for ROS detection. For flow cytometry analysis, cells were washed,
stained with fluorescently-tagged anti-Ly6G antibody, and fixed in 10% formalin after incubation
with bacteria.
In vitro PGE2 and PGE2 receptor antagonist treatment
Cells were treated with prostaglandin E2 (Cayman Chemical No. 14010) suspended in ethanol
and diluted in RP1-- for the indicated time periods prior to addition of bacteria and further
assessment of functionality. For antagonist experiments, cells were treated with EP-2 antagonist
PF-04418948 (Cayman Chemical No. 15016) or EP4-antagonist L-161,982 (Cayman Chemical
No. 10011565) suspended in DMSO and diluted in RP10- at a final concentration of 100 nM
concurrently with 1 uM PGE2.
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In vivo PGE2 and indomethacin treatment
For PGE2 supplementation, female B6 mice were injected i.p. with 40 μG 16,16 dM PGE2
(Cayman Chemical No. 14750) suspended in DMSO and diluted in sterile HBSS once daily,
beginning immediately after infection. Organs were harvested on day 4, homogenized, and plated
on BHI agar. For indomethacin challenge experiments, female BALB/c mice were injected i.p.
twice per day with 2 mg/kg indomethacin (Cayman Chemical No. 70270) suspended in DMSO
and diluted in sterile HBSS.
Statistical analysis
Statistical analysis was performed using Prism for Macintosh Version 6.0f (GraphPad).
Significance was determined using unpaired T-test unless otherwise noted. P-values < .05 were
considered significant and are indicated by * <.05, ** <.01, *** <.001, ****<.0001
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3. Type I IFN Does Not Promote Susceptibility to Foodborne Listeria monocytogenes
This chapter modified from a paper originally published as “Type I interferon does not promote
susceptibility to foodborne Listeria monocytogenes.” Pitts MG, Myers-Morales T, and D’Orazio
SE. The Journal of Immunology. 2016 Apr 1;196(7):3109-16. doi: 10.4049/jimmunol.1502192.
Tanya Myers-Morales assisted with completion of many of the experiments shown in this
manuscript.

Summary
Type I IFN (IFNα/β) is thought to enhance growth of the foodborne intracellular
pathogen Listeria monocytogenes (Lm) by promoting mechanisms that dampen innate immunity
to infection. However, the type I IFN response has been studied primarily using methods that
bypass the stomach and, therefore, fail to replicate the natural course of Lm infection. In this
study, we compared i.v. and foodborne transmission of Lm in mice lacking the common type I
IFN receptor (IFNAR1-/-). Contrary to what was observed using i.v. infection, IFNAR1-/- and
wild type mice had similar bacterial burdens in the liver and spleen following foodborne
infection. Splenocytes from wild type mice infected intravenously produced significantly more
IFNβ than those infected by the foodborne route. Consequently, the immunosuppressive effects
of type I IFN signaling, which included T cell death, increased IL-10 secretion, and repression of
PMN recruitment to the spleen, were all observed following i.v., but not foodborne transmission
of Lm. Type I IFN was also previously shown to cause a loss of responsiveness to IFNγ through
down-regulation of the receptor IFNGR1 on macrophages and dendritic cells.

However, we

detected a decrease in surface expression of IFNGR1 even in the absence of IFNα/β signaling,
suggesting that in vivo, this infection-induced phenotype is not type I IFN-dependent. These
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results highlight the importance of using the natural route of infection for studies of hostpathogen interactions and suggest that the detrimental effects of IFNα/β signaling on the innate
immune response to Lm may be an artifact of the i.v. infection model.

Introduction
Type I IFNs (IFNα/β) are multifunctional cytokines with diverse roles in anti-viral, antibacterial, and anti-tumor immunity. Over a dozen IFNα subtypes as well as a single
IFNβ subtype have been identified, and all of these bind the common type I IFN receptor
(IFNAR), a heterodimer composed of IFNAR1 and IFNAR2 (120, 121). Ligation of IFNAR,
which is expressed on a variety of immune cells, triggers Jak-Stat signaling and can affect the
expression of a diverse array of downstream genes (120). Secretion of type I IFN is induced by
ligation of Toll-like receptors and cytosolic sensors such as DDX41 and stimulator of interferon
genes (STING) (123, 124).
Studies using mice with a functionally inactivated type I IFN receptor (IFNAR1-/-)
demonstrated that IFNα/β signaling was essential for immunity to acute viral challenge. Despite
otherwise normal immune responses, these animals were unable to restrict replication of vesicular
stomatitis virus, Semliki Forest virus, or vaccinia virus after a low-titer challenge (131). Type I
IFN can directly limit the intracellular niche for viral replication by inducing expression of
cyclin-dependent kinase inhibitors, pro-apoptotic TRAIL and FAS/FASL, and the Mx-1 gene
(132, 133). These cytokines also stimulate dendritic cell maturation; upregulate expression of
MHC-I, MHC-II and costimulatory molecules; and promote the production of anti-viral
antibodies in B cells (134, 135). Although a robust type I IFN response is crucial for clearance of
most viruses, it has also been correlated with the development of more severe disease during
influenza virus infection (136, 137).
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The role of type I IFN in the response to bacterial challenge is complex and appears to
depend on the nature of the pathogen. Type I IFN signaling improved disease resistance in mice
infected with Group B streptococci, Streptococcus pneumoniae, and E. coli (138). In contrast,
type I IFNs have been characterized as detrimental to the host during infection with intracellular
bacterial pathogens such as Mycobacterium tuberculosis (139), Francisella tularensis (105),
Salmonella enterica (141), and Lm (142-144).

Studies using IFNAR1-/- mice suggest that

IFNα/β signaling can affect several key areas of innate immunity during infection with these
bacteria. During Lm infection, IFNα/β signaling inhibited macrophage responsiveness to IFNγ
and sensitized T cells to apoptotic signals (83, 144).

Type I IFN also limited neutrophil

recruitment to the spleen during both Francisella and Lm infection (105). Another study found a
higher frequency of TNFα-producing CD11b+ cells in the spleens of Lm-infected IFNAR1-/- mice
(142).

In each of these cases, mice that lacked type I IFN signaling resulted in infections had

either reduced bacterial burdens or more rapid bacterial clearance compared to wild type mice.
Lm is transmitted to humans through the ingestion of contaminated food, but innate
immunity to Lm is poorly understood because most studies have used either i.v. or i.p.
inoculation, methods that result in robust systemic growth of Lm without encountering the harsh
environment of the gastrointestinal tract. Some previous studies have used oral gavage to infect
mice; however, this delivery method can result in more rapid spread of Lm to the blood, spleen,
and liver with significant variability amongst investigators (57). All of these methods fail to
replicate the natural course of infection and therefore, disparate effects on host innate immunity
may be observed.
In this study, we compared foodborne transmission of Lm to i.v. infection to determine if
type I IFN secretion was detrimental to the host when the bacteria were introduced by the natural
route. We hypothesized that i.v. infection would trigger robust, rapid IFNβ secretion because a
bolus of bacteria reached the spleen within minutes of inoculation. Conversely, during foodborne
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infection, Lm would asynchronously arrive at the spleen over the course of two to three days.
Therefore, it was expected that foodborne transmission of Lm would not trigger a robust IFNα/β
response, and that the corresponding host-detrimental effects would not be observed.

As

predicted, we found that mice lacking the common type I IFN receptor were not more resistant to
foodborne Lm infection, and that foodborne infection triggered significantly less production of
IFNβ than i.v. infection. The data presented here suggest that most of the detrimental effects
attributed to type I IFN during Lm infection may actually be an artifact of the i.v. infection model.

3.1 IFNα/β receptor deficiency is not beneficial during foodborne Lm infection
After i.v. inoculation of Lm, IFNα/β receptor-deficient (IFNAR1-/-) mice resist high titer
growth in the spleen and clear the infection more quickly than wild type mice (142, 143).
Intravenously-injected Lm are quickly filtered from the blood by phagocytes in the spleen and
liver, producing a rapid-onset infection in these organs (78). However, i.v.-infected IFNAR1-/and wild type mice do not show a significant difference in Lm burdens until 2 days post-infection
(dpi), with maximal differences observed at 3 dpi (142). To find out if type I IFN signaling also
promoted the growth of Lm after oral transmission, we used a natural feeding model of Lm
infection. Groups of IFNAR1-/- and wild type C57BL/6 mice were fed a sublethal dose of Lm or
infected intravenously, and bacterial loads in the spleen and liver were compared. In agreement
with previous reports, the livers from IFNAR1-/- mice had more than 1000-fold fewer Lm
compared to wild type mice three days after i.v. infection (Fig. 3.1). In the spleen, IFNAR1deficient mice had 160-fold less Lm than wild type mice. In contrast, three days after foodborne
infection there was no significant difference in bacterial burdens in the liver, and the spleens of
IFNAR1-/- mice had only 20-fold fewer Lm than wild type mice (Fig. 3.1). These results are
similar to a recently published report by Kernbauer et al. who showed that i.g. infection of
IFNAR1-/- and wild type mice with Lm LO28 resulted in equivalent bacterial burdens in the
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spleen and liver 3 dpi (189). Even when foodborne infection was allowed to proceed for up to 5
days, there remained no significant difference between CFU counts in the liver, and differences in
the spleen were 5-fold or less. Notably, foodborne infection did not result in the death of any
mice during the 5-day observation period. Thus, while the lack of type I IFN signaling was
clearly beneficial after i.v. Lm infection, it did not alter the progression of foodborne listeriosis.

3.2 I.V. infection induces more robust IFNβ secretion than foodborne infection
In contrast to the rapid nature of i.v. infection, ingested Lm must first survive passage
through the stomach, invade the intestinal epithelium, and then gain access to the circulation via
the lymphatics before reaching the spleen. Depending on the size of the inoculum, this process
typically requires 24 to 48 hours after ingestion of contaminated food (35). With this in mind, we
hypothesized that the delayed and presumably asynchronous exit of Lm from the gastrointestinal
tract would trigger a less robust IFNα/β response than a bolus of organisms that arrived in the
spleen by i.v. inoculation. Consequently, a phenotype influenced by type I IFN signaling would
be more easily observed during i.v. infection than during foodborne infection.
To test this idea, splenocytes were harvested from mice 24 hours after i.v. or foodborne
infection (Fig. 3.2A), and lymphocytes were depleted to increase the concentration of
macrophages and dendritic cells in the samples. The cells were cultured overnight without
further stimulation, allowing for ex vivo accumulation of secreted cytokines, and ELISA was used
to quantify IFNβ. As shown in Fig. 3.2C, splenocytes from i.v.-infected mice produced more
IFNβ than did the splenocytes from mice infected by the foodborne route. However, a
considerable disparity existed in the bacterial burdens of these two groups at this time point. The
i.v. infected mice averaged 106 CFU in the spleen, while the orally challenged mice had less than
200 CFU per spleen (Fig. 3.2B).
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To find out if the bacterial burden or the route of transmission was the primary factor
influencing IFNβ secretion, we next established an infection model that resulted in colonization
of the spleen for similar periods of time with comparable bacterial loads. To accomplish this, the
i.v. dose was lowered to approximately 103 CFU and spleens were harvested 24 h after injection
(Fig. 3.2D). Foodborne infection, however, proceeded for 72 hours to give the bacteria time to
exit the G.I. tract and arrive in the spleen. This approach resulted in bacterial burdens of
approximately 104 CFU in all mice, and in both cases the bacteria had colonized the spleen for
approximately 24 hours (Fig. 3.2E). Splenocytes were then harvested and cultured overnight to
assess IFNβ production.

Despite the similarity in bacterial burdens, splenocytes from i.v.-

infected mice still produced significantly more IFNβ than cells from mice that had ingested Lm
(Fig. 3.2F). Because the murine common type I IFN receptor binds thirteen IFNα subtypes in
addition to a single IFNβ (120, 121), it was possible that IFNα secretion could also be influencing
the susceptibility of wild type mice to i.v. Lm infection. To test this, the splenocyte culture
supernatants were also assayed for IFNα; however, little or none was detected (Fig. 3.2G). Thus,
as predicted, i.v. infection resulted in a more robust type I IFN response than foodborne infection,
even when comparable bacterial burdens were present in the spleen. Furthermore, these results
suggested that enhancement of bacterial growth by the mechanisms previously attributed to
IFNα/β signaling might not occur during foodborne infection due to decreased production of type
I IFN.

3.3 T cell depletion in the spleen is a consequence of i.v., but not foodborne infection
One consequence of i.v. Lm infection that has been linked to type I IFN signaling is the
extensive loss of splenic lymphocytes that occurs within the first few days after infection. In wild
type mice inoculated intravenously with 0.1 LD50 of Lm, large numbers of splenic T cells
upregulated CD69 and underwent apoptosis, with cell death peaking by 3 dpi (190). When type I
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IFN signaling was absent, substantially less T cell depletion was observed in the spleen (144).
Since oral transmission of Lm did not induce robust IFNβ secretion, we hypothesized that there
would be little T cell loss in the spleen during foodborne listeriosis. To examine the extent of T
cell death, groups of wild type and IFNAR1-/- mice were challenged either i.v. or orally and the
total number of TCRβ+ cells in the spleen 3 dpi was compared to the cell counts of uninfected
mice. In agreement with previous work, i.v. infection induced an IFNAR1-dependent loss of
more than 50% of the TCRβ+ cells in the spleen (Fig. 3.3A). Following foodborne infection,
however, there was no significant T cell depletion in either wild type or IFNAR1-/- mice.
The presence of apoptotic cells and cellular debris can trigger the scavenger receptor
CD36 on macrophages, causing the cells to shift from a pro-inflammatory to a regulatory state
with concomitant production of IL-10 (191, 192). Because significant T cell loss was only
observed during i.v. infection, we predicted that i.v., but not foodborne Lm infection would result
in increased IL-10 production. To investigate this, spleens from infected wild type and IFNAR1-/mice were homogenized and the amount of IL-10 present was measured directly ex vivo. As
expected, spleens from wild type mice contained significantly more IL-10 than spleens from
IFNAR1-/- mice three days after i.v. infection (Fig. 3.3B). In contrast, splenic IL-10 production
did not increase significantly above the concentrations detected in uninfected mice either three or
four days after foodborne infection. Together, these results suggested that the IFNβ response
induced by foodborne infection was not substantial enough to trigger T cell loss and subsequent
increased IL-10 secretion in the spleen.

3.4 IFNα/β signaling does not affect PMN recruitment following foodborne Lm infection
Henry et al. previously showed that IFNAR1-deficient mice recruited significantly higher
numbers of PMN to the spleen following intranasal Francisella infection compared to wild type
mice (105). They proposed that a robust IFNα/β response limited the early influx of PMN by
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preventing γδ T cell expansion and production of IL-17, thereby reducing the ability of wild type
mice to eliminate bacteria in the early stages of infection.

Based on this observation, we

hypothesized that the modest IFNβ response triggered by foodborne Lm infection would not alter
PMN recruitment to the spleen, while robust secretion of IFNβ following i.v. infection would
limit this influx.
To test this, the total number of PMN (Ly6GhiLy6CintCD11b+) in the spleens of wild type
and IFNAR1-deficient mice was determined by flow cytometry. Spleens were harvested 48 h
after i.v. infection and 72 h after foodborne infection. As shown in Fig. 3.4A, i.v. infection of
IFNAR1-deficient mice resulted in a greater PMN influx to the spleen compared with wild type
mice. Three days after foodborne infection, however, there was no difference in the number of
PMN in the spleens of IFNAR1-/- and wild type mice. Thus, PMN recruitment to the spleen was
strongly enhanced by the loss of type I IFN signaling during i.v. infection, but not during
foodborne infection. These data again suggested that the type I IFN response induced during
foodborne listeriosiss was not robust enough to alter the innate immune response necessary for
early clearance of Lm.

3.5 IFNGR1 expression decreases on splenic macrophages and dendritic cells during both
i.v. and foodborne infection
IFNβ was also shown to negatively regulate transcription of the receptor for interferon
gamma (IFNGR1), thereby limiting the ability of macrophages to respond to the presence of IFNγ
(82, 83). This would presumably result in less killing of intracellular bacteria and provide a more
hospitable replicative niche for the growth of Lm in vivo.

Based on the differential IFNβ

secretion we detected, we hypothesized that decreased surface IFNGR1 expression would be
observed shortly after i.v. infection, but not following the ingestion of Lm-contaminated food.
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To test this, splenocytes were harvested from mice 24 hours after i.v. infection, and the
mean fluorescence intensity (MFI) of IFNGR1 on the surface of macrophages, dendritic cells, B
cells, and T cells was determined directly ex vivo (Fig. 3.5A). Although i.v. infection with 103
CFU resulted in robust IFNβ secretion (Fig. 3.2B), little to no decrease in IFNGR1 expression
was observed in any of the four cell types examined (Fig. 3.5B). However, in agreement with
previous studies, when we increased the inoculum to 104 CFU, IFNGR1 expression on
CD11chiF4/80-/lo dendritic cells and F4/80hiCD11c-/lo macrophages decreased to levels that were
approximately 50% of that found on uninfected cells. In contrast, B cells showed little to no
change in IFNGR1 levels during high titer i.v. infection, and T cells showed an increase above
uninfected levels (Fig. 3.5B). These results suggested that dose-dependent decreases in IFNGR1
expression occurred primarily on myeloid-derived antigen-presenting cells and that a bacterial
burden of at least 105 CFU in the spleen (Fig. 3.5C) was required to observe this effect following
i.v. challenge. At 24 hours after foodborne infection, little to no decrease in IFNGR1 MFI was
seen on any of the four cell types tested (Fig. 3.5D). This observation was not surprising, since
few mice had detectable bacterial loads in the spleen 24 hpi (Fig. 3.5E). By 48 hpi, however,
IFNGR1 MFI had decreased by approximately 50% on dendritic cells and macrophages, despite
the fact that bacterial burdens in the spleen averaged only 102 CFU at this time point. By 72 hpi,
the MFI of IFNGR1 on dendritic cells and macrophages had decreased to levels similar to those
seen during high dose i.v. infection. However, as shown in Fig. 3.5D, at this time point the mice
had only ~104 CFU in the spleen, a bacterial burden that did not trigger changes in IFNGR1 MFI
during i.v. infection (Fig. 3.5C). Thus, down regulation of IFNGR1 expression during foodborne
infection was dependent on bacterial load in the spleen, but occurred at a significantly lower
threshold than during i.v. infection.
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3.6 Infection-induced decreases in IFNGR1 expression are not dependent on type I IFN
signaling
The changes in IFNGR1 levels observed during foodborne infection in the absence of
robust IFNβ secretion hinted that surface expression of this receptor might not be strictly
dependent on the presence of a type I IFN signal. To directly assess the role of IFNα/β signaling
in down regulation of IFNGR1, groups of wild type and IFNAR1-/- mice were given a high-titer
dose of Lm intravenously or fed 109 CFU of Lm and IFNGR1 levels were assessed directly ex
vivo by flow cytometry. As shown in Fig. 3.6A, IFNGR1 expression on dendritic cells and
macrophages decreased by approximately one-half in IFNAR1-/- mice, equivalent to or in some
cases greater than the change seen on cells from wild type mice. For both groups of mice, B cell
IFNGR1 expression underwent little change, while expression of this receptor on T cells
increased. Thus, infection-induced down-regulation of IFNGR1 was not dependent on type I
interferon signaling.
A variety of cells rapidly produce IFNγ during Lm infection (81, 193, 194) and the
cytokine can be detected in the blood within 24 to 48 hours of either i.v (142, 143) or foodborne
(unpublished observation, Bou Ghanem and D’Orazio) transmission. Therefore, it was possible
that ligand binding could trigger internalization of IFNGR1 and contribute to the observed
decrease in surface expression during the timeframe we tested.

If this was the case, then

infection-induced decreases in IFNGR1 expression should be greater in wild type mice than in
IFNγ-deficient mice (IFNγ-/-). To test this, groups of mice were infected i.v. and IFNGR1
expression was assessed 24 hours later. As shown in Fig. 3.6B, dendritic cells and macrophages
from IFNγ-/- mice showed significantly less down-regulation of IFNGR1 than did cells from wild
type mice. Although IFNγ-/- mice are more susceptible to Lm infection over time, there was no
significant difference in Lm burdens between IFNγ-/- and wild type mice 24 hpi (Fig. 3.6C).
Thus, the difference in IFNGR1 expression was not the result of a disparity in bacterial loads.
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These results indicated that multiple mechanisms could contribute to decreased surface
expression of IFNGR1 during infection, and suggested that this phenotype did not contribute
significantly to the enhanced growth of Lm in IFNAR1-deficient mice.

3.7 Discussion
Intravenous infection of mice results in a highly reproducible model of systemic
listeriosis; however, this method fails to replicate the natural course of infection, which originates
in the gastrointestinal tract following the consumption of Lm-contaminated foods. Previous
studies using i.v. inoculation have suggested that secretion of type I IFN during the early stages of
listeriosis may promote growth of Lm (142, 143). In this study, we demonstrated that foodborne
infection of mice did not elicit a robust type I IFN response in the spleen. Accordingly, the hostdetrimental effects caused by IFNα/β signaling were not observed when Lm were transmitted by
the oral route. The results presented here highlight the necessity of using physiologically relevant
infection models to address questions regarding the host immune response to infection.
Intravenous inoculation is widely used for studies of immunity to Lm because it produces
a robust infection in mice, with up to 90% of the initial inoculum seeding the spleen and liver
within 15 minutes (78). Lm are thought to be removed from the blood by phagocytes surrounding
the marginal zone of the spleen. These cells transport Lm to the periarteriolar lymphoid sheath,
where increases in bacterial burden can be detected as early as 6 hpi (195). In contrast to the
rapid nature of i.v. infection, orally acquired Lm typically require 24-48 hours to exit the
gastrointestinal tract and begin colonizing the spleen (35, 196, 197). To reach the spleen, Lm must
survive in the harsh environment of the stomach, invade the intestinal epithelium, disseminate to
the mesenteric lymph nodes, and then gain access to the circulation. The specific timing of these
events is unclear, but because of the bottlenecks involved in this process small numbers of Lm are
likely to exit the intestine in waves, rather than as a bolus. It is interesting to note that i.p.
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inoculation, which also involves an indirect route of spread to the spleen, does trigger IFNα/βdependent effects that promote Lm growth (144, 198). We speculate that dissemination of Lm
from the peritoneum to the spleen occurs more rapidly than spread from the intestinal lamina
propria, presumably because there are fewer bottlenecks to overcome.
Our results differ from that of Kernbauer et al., who recently concluded that type I IFN
signaling promotes resistance to oral Lm infection because they found that approximately 30% of
IFNAR1-/- mice died within 5 days after intragastric (i.g.) inoculation (189) . There are two key
differences between our studies. First, Kernbauer et al. used two separate i.g. injections (200 µl of
bicarbonate, and then 200 µl of bacteria) to orally infect mice. I.g. infection is a more physically
traumatic method than natural feeding and may promote a pathway of direct bloodstream
invasion in a user-dependent manner (57). However, such physical trauma would be expected to
result in an infection that mimicked i.v. inoculation, and neither our group, nor O’Connell et al.
saw increased death of i.v.-infected IFNAR1-/- mice compared to wildtype animals (143). Thus,
the more likely explanation for the unique result in the Kernbauer et al. study is that they used Lm
LO28, a strain that overexpresses the multidrug efflux pumps MdrM and MdrT due to a
spontaneous deletion in the TetR repressor (126, 199, 200). This results in increased secretion of
c-di-AMP, greater IRF3 signaling, and hyper-induction of type I IFN compared to either the
commonly used laboratory strains EGDe or 10403s or other clinical isolates of Lm.
Myeloid-derived cells rapidly initiate IFNβ production after exposure to Lm. In vitro
infection of bone marrow-derived macrophages and dendritic cells resulted in a clear induction of
IFNβ mRNA as early as 4-6 hpi (143, 201), and intracellular cytokine staining of Lm-pulsed
dendritic cells verified that IFNβ protein was secreted 6 hpi (202). In this study, we manipulated
the dose and duration of Lm infection to yield similar bacterial burdens in the spleen after oral
and i.v. challenge, but found that i.v. inoculation still induced significantly more secretion of
IFNβ from splenocytes than foodborne infection. The simplest interpretation of these results is
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that the impetus for robust IFNβ secretion is a sudden exposure to a large bolus of bacteria, which
infection by the foodborne route would not provide. There are very few published reports that
have measured IFNα levels by ELISA during bacterial infection. However, the amount of IFNβ
secreted by splenocytes from i.v.-infected mice in this study was similar to that observed in
mouse serum after cecal ligation and puncture (203) and from primary mouse lung fibroblasts
following in vitro Chlamydia trachomatis infection (204). We were unable to detect increased
IFNα in the spleen during i.v. or foodborne infection, despite the fact that IFNα subtypes
outnumber IFNβ by a large ratio (121). Notably, previous measurements of IFNα concentrations
in either serum or spleen ranged from 30-50 pg/mL 24 hours after i.v. Lm infection (205, 206).
This may indicate that IFNα is produced by cell types that we did not include in high numbers in
our splenocyte cultures.
Robust IFNβ secretion following i.v. inoculation of Lm triggered significant T cell loss,
IL-10 secretion, and a dampening of PMN recruitment in the C57BL/6 mice used in this study.
These findings are consistent with previous studies that suggested type I IFN was detrimental to
the host during Lm infection (105, 142-144).

None of these IFNβ-dependent effects were

observed during foodborne infection. Surprisingly, down-regulation of IFNGR1, a phenotype
that was previously linked to the induction of type I IFN (82, 83), occurred during both i.v. and
foodborne infection. Our findings support those of Rayamajhi et al. (83) who found that IFNGR1
down-regulation was primarily observed in myeloid-derived cells. They showed that a soluble
factor was responsible for suppression of IFNGR1 expression during in vivo Lm infection and
used in vitro treatment of bone-marrow derived macrophages to demonstrate that IFNβ could
induce this phenotype. Our findings, however, indicate that IFNα/β signaling is not absolutely
required for IFNGR1 down-regulation to occur in vivo and suggest that a variety of other signal
inputs may influence surface expression of this receptor. For example, IFNγ is quickly produced
by a variety of cells in the spleen during Lm infection (81, 193, 194), and rapid endocytosis of
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IFNGR1 due to ligand binding is likely to occur. Non-ligand based interactions could also
promote internalization of IFNGR1, as has been shown to occur on T cells following TCR
engagement (207). Prior in vitro work has shown that IFNα/β may act as an antagonist for
IFNGR1 (208); however, it is unclear whether in vivo infection would induce the concentrations
necessary to achieve these effects.
Type I IFN has traditionally been thought of as an immunostimulatory agent critical for
inducing an anti-viral response, but it is also commonly used to treat autoimmune diseases such
as relapsing-remitting multiple sclerosis (209). Thus, the actions of type I interferons are contextdependent and may be either pro-inflammatory or anti-inflammatory (210, 211). The timing of
IFNα/β secretion, and the concentration present in any given tissue, are likely to be primary
factors in determining the downstream effects of a type I IFN response. Future studies of
microbial pathogens and the type I IFN response to infection should take into account the impact
that route of transmission may have on both the induction and the effects of this uniquely
multifunctional family of cytokines.
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Figure 3.1 Foodborne Lm infection of IFNAR1-/- and wild type (WT) C57BL/6J mice
results in similar burdens in the liver and spleen.
Mice were infected i.v. with 9.0 x 104 CFU or fed 109 CFU of Lm SD2000. Data from
multiple experiments was pooled for a total of 8-10 mice per group except for the 5 dpi time
point, which includes 3-6 mice per group. Mean values +/- SD are shown.
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Figure 3.2 Robust IFNβ secretion is induced by i.v., but not foodborne Lm infection.
Splenocytes were harvested from infected C57BL/6J mice and a portion was used to determine
total CFU burden. B and T cells were depleted from the remaining splenocytes, and the cells
were cultured overnight to allow for ex vivo accumulation of secreted IFNα/β.

(A), (D),

Graphical depictions of infection strategies used are shown. (A) Mice were inoculated i.v. with 5
x 104 CFU or fed 109 CFU of Lm SD2000 and spleens were harvested 24 h later. In panel (D), a
lower i.v. dose was used (1 x 103 CFU) and spleens were harvested 24 h after i.v. and 72 h after
foodborne infection. (B), (E), Total CFU burdens per spleen are shown. (C), (F), (G), IFNβ or
IFNα ELISA data are shown. Representative values from one of three (IFNβ) or two (IFNα)
separate experiments using 2-3 mice per group are shown. Horizontal lines indicate mean values
for each group; dashed lines indicate limits of detection. NI, not infected.

57

Figure 3.3 IFNα/β signaling does not promote T cell loss or IL-10 induction during
foodborne listeriosis.
C57BL/6J (WT) and IFNAR1-/- mice were infected i.v. with 5-6 x 104 CFU or fed 109 CFU of
Lm SD2000. Splenocytes were harvested at the indicated time points, and the total number of
T cells per spleen (A) and the concentration of IL-10 present in clarified spleen homogenates
(B) was determined. Pooled data from multiple experiments are shown. For panel A, values
for each mouse are shown and horizontal lines indicate means for each group. For panel B,
mean values +/- SD are shown; n=6-7 mice per group except WT NI, where n=4. NI, not
infected.
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Figure 3.4 A lack of type I IFN signaling enhances PMN recruitment to the spleen during
i.v., but not foodborne infection.
Mice were infected i.v. with 1 x 104 CFU or fed 109 CFU of Lm SD2000 and splenocytes were
harvested at either 2 dpi (i.v.) or 3 dpi (food).

A) The total number of PMN per spleen is

shown. B) Total Lm burdens per spleen are shown; dashed line indicates limit of detection.
Data from multiple experiments were pooled; mean values are indicated by grey bars (A) or
horizontal lines (B).
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Figure 3.5 Lm infection results in decreased IFNGR1 expression on macrophages and
dendritic cells.
Mice were infected i.v. with the indicated doses and splenocytes were harvested 24 hpi (B, C) or
mice were fed 109 CFU, with splenocytes harvested at the indicated time points (D, E). A
representative histogram depicting the shift in IFNGR1 expression on dendritic cells 24 h after
i.v. infection is shown in panel (A). Mean fluorescence intensity values (MFI) for IFNGR1 were
normalized to the MFI for uninfected splenocytes, which is represented by the dotted line at 1.0
(B, D). DC, dendritic cell; MΦ, macrophage. Significance was determined using one-sample ttest; asterisks indicate mean values significantly different from a hypothetical mean of 1.0. (C, E)
Total Lm CFU per spleen was determined at indicated time points; dashed line indicates limit of
detection.
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Figure 3.6 Infection-induced decreases in IFNGR1 expression are not type I IFNdependent.
A) IFNAR1-/- and C57BL/6J (WT) mice were i.v. infected with 4.0 x 103 CFU or fed 109 CFU
Lm SD2000 and spleens were harvested at 24 (i.v.) or 72 (food) hpi. Mean fluorescence
intensity values (MFI) for IFNGR1 were normalized to the MFI for uninfected splenocytes,
which is represented by the dotted line at 1.0. DC, dendritic cell; MΦ, macrophage. Mean
values +/- SD are shown; data was pooled from multiple experiments, n= 4-7 mice per group.
(B, C) IFNγ-/- and C57BL/6J (WT) mice were i.v. infected with 1 x 104 CFU of Lm. Spleens
were harvested 24 hours later and IFNGR1 MFI (B) and total CFU burden (C) was
determined. Data from two experiments was pooled; horizontal lines indicate mean values.
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4. Neutrophils from susceptible and resistant mice efficiently kill opsonized Listeria
monocytogenes
This chapter modified from “Neutrophils from susceptible and resistant mice kill Listeria
monocytogenes similarly in vitro.” Pitts, M.G., Combs, T.A., and D’Orazio, S.E.F. Infection and
Immunity Apr. 2018: 86 (4). doi: 10.1128/IAI.00085-18
Travis A. Combs contributed to the design and completion of the work shown in figure 2.

Summary
Inbred mouse strains differ in their susceptibility to infection with the facultative
intracellular bacterium Listeria monocytogenes (Lm), largely due to delayed or deficient innate
immune responses. Previous antibody depletion studies suggested that PMN were particularly
important for clearance in the liver, but the ability of PMN from susceptible and resistant mice to
directly kill Lm has not been examined. In this study, we showed that PMN infiltrated the livers
of BALB/c/By/J (BALB/c) and C57BL/6 (B6) mice in similar numbers and both cell types
readily migrated towards leukotriene B4 in an in vitro chemotaxis assay. However, CFU burdens
in the liver were significantly higher in BALB/c mice, suggesting that PMN in the BALB/c liver
might not be able to clear Lm as efficiently as B6 PMN. Unprimed PMN harvested from either
BALB/c or B6 bone marrow killed Lm directly ex vivo, and pretreatment with autologous serum
significantly enhanced killing efficiency for both. Lm were internalized within 10 minutes and
rapidly triggered intracellular production of reactive oxygen species in a dose-dependent manner.
However, PMN from gp91phox-deficient mice also readily killed Lm, which suggested that nonoxidative killing mechanisms may be sufficient for bacterial clearance. Together, these results
indicate that there is not an intrinsic defect in the ability of PMN from susceptible BALB/c mice
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to kill Lm and further suggest that if PMN function is impaired in BALB/c mice, it is likely due to
locally produced modulating factors present in the liver during infection.

Introduction
Lm are facultative intracellular bacteria that cause foodborne disease in humans. In
mouse models of listeriosis, orally transmitted Lm establish infection in the gut, and then spread
systemically to the spleen, liver, and gall bladder (35, 71). Susceptibility to listeriosis varies
among inbred mouse strains; for example, bacterial burdens rise to significantly higher levels and
clearance is delayed in BALB/c mice compared to C57BL/6 (B6) or C57BL/10 mice (35, 46,
212). This difference has been attributed primarily to facets of innate immunity, including
differential expression of STAT4 and reduced or delayed secretion of TNFα, IL-12, and IFNγ
(47-50).
One mechanism for innate clearance of Lm is direct killing by neutrophils (PMN). Early
work to deplete PMN from mice relied on an antibody (clone RB6-8C5) that was subsequently
shown to bind both PMN and monocytes (94-98). More recent depletion strategies designed to
avoid this issue yielded conflicting results about the importance of PMN for clearance from the
liver (91, 99). PMN in the liver could either kill bacteria released from apoptotic hepatocytes or
may directly lyse infected hepatocytes, releasing the bacteria from a protective niche (62, 89, 90).
Despite PMN recruitment to the liver, CFU burdens in BALB/c mice increased steadily for
approximately 5 days; in contrast, exponential growth of Lm was restricted in B6 livers and the
number of CFU began to fall after approximately 3 days (35, 46). This suggests that BALB/c
PMN might be less efficient at killing Lm than B6 PMN.
PMN make up the majority of immune cells in human blood, but only account for about
15% of circulating immune cells in the mouse (102, 113). Since human blood is readily available
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in larger quantities than murine blood, human PMN are most commonly used for in vitro assays
that study interactions of PMN with bacteria.

Murine PMN lack defensins and have a low

affinity for the prototypical formylated peptide fMLF, but they do possess a strong affinity for
formylated peptides derived from Lm and Staphylococcus aureus (110, 112, 116). Differences in
relative speed and migration distance have also been noted when using murine and human PMN
were compared in chemotaxis assays (117). The difficulty in obtaining large numbers of PMN
from mice and the potential for functional differences with human cells has resulted in a lack of
studies using murine PMN. However, PMN isolated from human peripheral blood cannot be
used to evaluate how PMN contribute to susceptibility or resistance in mouse models of infection.
It has been estimated that mature PMN remain in the bone marrow of mice for up to 2
days before being released into circulation (101). Boxio et al. first showed that mouse bone
marrow is an abundant source of morphologically mature PMN and that these cells release both
primary and secondary granules upon stimulation (114). Swamydas et al. further refined the
enrichment protocol and showed that PMN harvested from bone marrow could be used for
adoptive transfer (115). In this study, we used PMN enriched from the bone marrow of naïve or
infected BALB/c and B6 mice and compared the ability of the cells to kill Lm directly ex vivo.
We demonstrate that murine neutrophils efficiently kill serum-opsonized Lm using both oxidative
and non-oxidative mechanisms. We concluded that there were no intrinsic differences in the
capacity of PMN from susceptible BALB/c and resistant B6 mice to directly kill Lm.

4.1 Hepatic PMN infiltration after foodborne infection is similar in BALB/c and B6 mice
Using the foodborne model of listeriosis in mice, Lm colonize the gut tissue for 24-48
hours and then spread systemically to the spleen and liver (35, 147).

Differences in host

susceptibility to infection can readily be observed in the liver, where the number of CFU in
susceptible BALB/c mice is significantly greater than in the more resistant B6 mice (Fig. 4.1A)
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(35). PMN-rich hepatic abscesses containing Lm were observed in both BALB/c and B6 mice 24
hours after intravenous infection (53). To verify that PMN were recruited to the liver parenchyma
after foodborne infection, livers were harvested after portal vein perfusion to remove blood and
Ly6Ghi cells were identified by flow cytometry. At 3 dpi, there was a five to ten-fold increase in
the number of PMN in the liver, with no significant difference observed between BALB/c and B6
mice (Fig. 4.1A). Thus, a lack of PMN infiltration did not explain the greater CFU burden in the
BALB/c liver.
After reaching a tissue such as the liver, PMN must further sense and then migrate
towards specific chemoattractants, a process that was recently shown to create a “swarm” at
infectious foci (108). To test whether BALB/c cells had a chemotaxis defect, we analyzed the
ability of gradient- enriched PMN to migrate towards specific signals using an under-agarose
assay. We first tested Lm-derived formylated peptides, which were previously shown by Liu et
al. to induce chemotaxis from mouse PMN in a Boyden chamber assay (111). A combination of
two formylated peptides (1 µM fMIVTLF plus 1µM fMIGWII) did not induce migration in the
under-agar assay, despite triggering a burst of intracellular ROS when applied to either BALB/c
or B6 PMN, likely a result of low diffusion through the matrix (data not shown). However,
leukotriene B4, a lipid-derived chemotactic signal produced by PMN (106), did induce migration
of gradient-enriched murine PMN. The maximum distance traveled in three hours was
approximately 900 μm for both BALB/c and B6 PMN (Fig. 4.1B). Together, these data indicated
that recruitment of circulating PMN and chemotaxis towards PMN-derived stimuli was similar in
both susceptible BALB/c mice and resistant B6 mice.
4.2 Unprimed bone marrow PMN rapidly kill Lm in the presence of autologous serum
Although there was no difference in PMN infiltration, increased bacterial growth in
BALB/c mice could also be due to an intrinsic defect in the ability of BALB/c PMN to kill Lm.
To test this, we developed an in vitro killing assay using PMN isolated from the bone marrow of
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uninfected mice. PMN were enriched using gradient centrifugation, a method that typically
yielded a 65-80% pure population of Ly6Ghi PMN (Fig. 4.2A). The remaining cells were Ly6Chi
monocytes (1-5%), CD19+ B cells (10-20%), and a small number of CD11b+ CD64- cells (data not
shown). The enriched PMN were transferred to a 96-well flat-bottom plate and incubated with
Lm at low MOI for 90 minutes. As shown in Fig. 4.2B, there was only a 20% decrease in
detectable CFU within this time frame using PMN from either mouse strain.
Bortolussi et al. previously showed that Lm uptake by human PMN was greatly enhanced
when serum was present (67). To find out if killing efficiency could be improved by exposure to
serum proteins, we pre-treated late stationary phase bacteria with 10% autologous mouse serum
for 30 min. prior to the addition of PMN.

As shown in Fig. 4.2C, serum pre-treatment

significantly increased the killing rate within one hour for both BALB/c and B6 PMN. In
contrast, pre-treatment with heat-inactivated serum did not enhance killing of Lm. Thus, a heatlabile component found in naïve serum, most likely complement, contributed significantly to the
ability of PMN to kill Lm in vitro. Accordingly, serum pre-treatment was used for all subsequent
killing assays.
In the killing assays described above, the percentage of Lm killed was calculated by
comparing the number of CFU recovered in the presence of PMN to the number of CFU found in
assay wells that contained only bacteria. Incubation of Lm in tissue culture media for one hour
resulted in an approximate doubling of the bacteria (Fig. 4.2D), a pattern that was consistently
observed in all assays. The number of CFU recovered after the addition of gradient-enriched
PMN was significantly less than the initial inoculum (dashed line), demonstrating that the PMN
were actively killing bacteria within 1 h rather than simply inhibiting growth. However, given
that the PMN out-numbered the bacteria in these assays by up to 10-fold, it was surprising that so
many viable Lm remained in each well. To find out if a longer incubation time would allow the
PMN to completely clear the inoculum, the killing assay was extended to four hours. Lm
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incubated in tissue culture media alone increased more than 30-fold during this time frame (Fig.
4.2D). When PMN were added, the number of Lm was five-fold higher than the initial inoculum
but this number represented an approximate 80% killing rate compared to bacterial growth
without PMN. Thus, prolonged incubation time did not increase the efficiency of killing, and
extending the incubation period just allowed any bacteria that evaded contact with PMN to
replicate exponentially.

4.3 Sorted bone marrow PMN maintain viability and killing capacity after in vitro culture.
Although gradient centrifugation provided a substantially enriched PMN population to
study, it was unknown whether any of the killing observed could be ascribed to the contaminating
cells, which typically made up 20-35% of the enriched population. To investigate this, three
populations of cells were sorted from BALB/c and B6 bone marrow:

Ly6GhiLy6C+ PMN,

Ly6ChiLy6G- monocytes, and the residual Ly6G-Ly6C- cells (Fig. 4.3A). Each population was
plated separately and incubated with Lm for one hour. As shown in Fig. 4.3B, sorted PMN from
both BALB/c and B6 mice killed nearly 80% of the bacteria.

Neither monocytes nor the

residual population of primarily B cells were capable of killing the bacteria directly ex vivo.
These results indicated that murine bone marrow PMN could be sorted without deleterious effects
and suggested that the killing observed with gradient-enriched cells was attributable only to the
PMN.
To assess the functional ex vivo lifespan of murine bone marrow PMN, sorted cells were
cultured overnight and inoculated with Lm the following day. As shown in Fig. 4.3C, PMN
remained capable of killing 60 to 70% of the inoculum after 24 hours of in vitro culture.
However, in contrast to what was observed directly ex vivo, Ly6Chi monocytes also killed
approximately 60% of bacteria. Surprisingly, even the other cells, which were comprised mainly
of CD19+ B cells, killed 30-40% of the Lm (Fig. 4.3C). Therefore, murine PMN are viable and
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retain efficient killing ability for at least 24 hours after isolation from the bone marrow.
However, these data indicate that only highly purified sorted PMN should be used for
experiments involving cells maintained in culture for more than a few hours.

4.4 Bone marrow PMN rapidly internalize and kill Lm intracellularly.
Human PMN are known to phagocytose particulate matter within seconds, followed by
rapid closure of the phagosome, which then fuses with granules containing an array of
antibacterial compounds (213). Extracellular killing mechanisms such as PMN extracellular traps
have also been described (214). To assess the importance of bacterial internalization for in vitro
killing of Lm, sorted PMN were pre-treated with cytochalasin D, an inhibitor of actin
polymerization. Lm constitutively expressing GFP were added and differential “in/out” staining
was performed 10 minutes later.

Non-permeabilized cells were stained with Texas Red-

conjugated polyclonal anti-Lm antibodies such that cell-associated extracellular bacteria appeared
yellow (Fig. 4.4A). Bacteria that were internalized by the PMN, and thus, not accessible to the
antibodies, appeared green. As shown in Fig. 4.4A, approximately 90% of the cell-associated Lm
were intracellular 10 minutes after incubation with either BALB/c or B6 PMN. Pre-treatment
with cytochalasin D decreased the percentage of intracellular bacteria, but did not completely
block uptake. Killing assays performed simultaneously also showed a significant reduction in the
percentage of bacteria killed when cytochalasin D was used (Fig. 4.4B). These results indicated
that phagocytosis contributes to the ability of mouse bone marrow PMN to efficiently kill serumopsonized Lm.
To investigate the possibility that Lm might be efficiently internalized by murine PMN
but not killed within the short time period of these assays, a gentamicin protection assay was
performed to quantify intracellular bacteria.

Lm was added to gradient-purified PMN, and

gentamicin was added 10 min later. As shown in Fig. 4.4C, 10 ug/ml gentamicin was sufficient
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to kill 100% of the 1 x 105 CFU added to each well in the absence of PMN. At t=25 min, 50-200
gentamicin-resistant CFU were detected per well (0.05-0.2% of the initial inoculum).

The

number of intracellular Lm did not change at 35 or 45 minutes post-infection (Fig. 4.4C). These
data suggested that a small number of Lm may be able to avoid killing and survive intracellularly.
However, the negligible number of gentamicin-resistant bacteria were not likely to influence the
percent killed calculations in the in vitro killing assays.

4.5 Lm induces a respiratory burst in unprimed murine PMN
One of the ways PMN can kill bacteria is though targeted release of reactive oxygen
species (ROS). To measure the induction of ROS in PMN exposed to Lm, dihydrorhodamine 123
(DHR) fluorescence was used. DHR diffuses across the cell membrane and fluoresces when
oxidized to rhodamine by either peroxynitrite, a product of nitric oxide and superoxide, or
hypochlorous acid (215). The short incubation period of the assays described here was not likely
to activate iNOS (216, 217); therefore, in this system, DHR served primarily as a measure of the
amount of hypochlorous acid produced by the PMN.
Gradient-enriched PMN from BALB/c and B6 mice were incubated in media for one
hour, and then suspended in buffer prior to the addition of serum-opsonized Lm. As shown in
Fig. 4.5A, when the bacteria were added at a low MOI, less than 25% of the PMN produced ROS
within 30 minutes. When 10-fold more bacteria were added, the number of ROS-positive cells
increased significantly for both BALB/c and B6 PMN. Thus, unprimed PMN from both mouse
strains rapidly responded to the presence of Lm by producing ROS in a dose-responsive manner.
Although increasing the MOI resulted in a more robust respiratory burst, the killing efficiency
remained at 60 to 80% (Fig. 5.5B), as was observed previously for assays using lower MOI
(compare to Fig. 2C, 3B, and 4B). Together, these observations suggested that ROS might not be
required for efficient killing during the in vitro assay.
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4.6 Murine PMN use both oxidative and non-oxidative mechanisms to kill Lm
To specifically assess the importance of ROS for killing of Lm, PMN from gp91phoxdeficient mice were compared to wild type B6 PMN. These mice lack a functional allele for the
large gp91 subunit of NADPH oxidase; thus, the enzyme cannot assemble (218). As shown
previously, there was a dose-dependent response for wildtype B6 PMN, with an MOI of 10
inducing more ROS-positive cells than even PMA treatment (Fig. 6A). PMN from gp91phoxdeficient mice produced no detectable ROS at low MOI or after treatment with PMA, but, 2-5%
of the cells became rhodamine-positive when Lm was added at an MOI of 10. A simultaneous
killing assay done with these cells showed that gp91phox-/- PMN were equally capable of killing
Lm as cells from the wild type NADPH oxidase-sufficient mice, regardless of the MOI used (Fig.
4.6A). Thus, in genetically deficient mice that were unable to produce ROS from birth, nonoxidative mechanisms were sufficient to kill Lm.
As an alternate approach to block ROS activity in both BALB/c and B6 mice, 4-hydroxy
Tempo (Tempol) was used to scavenge superoxide produced in response to Lm. Tempol is a
pleiotropic antioxidant with both superoxide dismutase and catalase-like properties (219, 220).
Gradient-enriched PMN were pre-treated with Tempol for 90 minutes prior to the addition of Lm,
and DHR was added to the samples to report generation of ROS. As shown in Fig. 4.6B,
approximately 20-30% of either BALB/c or B6 PMN produced high levels of ROS within 30
min, and pre-treatment with Tempol significantly reduced the percentage of ROShi cells detected.
Tempol treatment also resulted in a 10-15% reduction in killing by PMN from both mouse strains
(Fig 4.6B). These data indicated that in mice genetically capable of producing ROS, scavenging
oxidative intermediates such that less hypochlorous acid was available reduced killing efficiency
in PMN. However, these data were also consistent with the conclusion that oxidative killing
mechanisms are not required to eliminate Lm.
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Since oxidative mechanisms were not required to kill Lm, we hypothesized that inhibition
of proteases such as elastase, cathepsin G, and proteinase 3 would result in at least partial loss of
killing

capacity.

To

test

this,

gradient-enriched

PMN

were

incubated

with

diisopropylfluorophosphate (DFP), a non-specific serine protease inhibitor. DFP was previously
reported to inhibit protease activity without affecting production of ROS (221). Treatment with 5
mM DFP resulted in a significant reduction in PMN killing ability (Fig. 4.6C). However,
treatment with 5 mM DFP also completely inhibited the ROS response in PMN exposed to Lm.
Lowering the concentration to 0.2 mM DFP eliminated the effect on ROS activity, but this
concentration did not inhibit bacterial killing (Fig. 4.6C). Therefore, it was not possible to
determine whether the loss of killing efficiency was due to a loss of serine protease activity or a
reduction in ROS availability in wildtype mice. DFP treatment of PMN from gp91phox-deficient
mice, however, did result in a significant loss of killing, suggesting that full protease activity is
important for optimal killing in the absence of ROS (Fig. 4.6D).

4.7 PMN harvested from the bone marrow of infected BALB/c and B6 mice kill Lm with
similar efficiency
Since murine PMN largely stay sequestered in bone marrow until receiving a chemotactic
signal to egress into the circulation, the cells used in our in vitro assays were likely to be less
activated than cells that are primed to infiltrate infected tissues. To assess the ability of activated
cells to kill Lm, we harvested bone marrow from BALB/c and B6 mice 2 days after foodborne
infection with Lm. At this time point, there are typically no CFU in the bone marrow; however,
there are cells producing IFNγ, and monocytes still in the marrow have undergone inflammatory
changes (75). Likewise, PMN in the marrow of both BALB/c and B6 mice had uniformly
upregulated CD11b expression (Fig. 4.7A). CD11b is a component of complement receptor 3,
and it was previously shown that CD11b increased on the surface of human PMN after activation
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(222-224). However, no significant differences were observed for the ability of CD11bhi PMN to
kill Lm in vitro compared to cells from uninfected mice (Fig. 4.7A). Thus, unprimed cells from
the marrow of uninfected mice behaved very similarly to primed cells from the marrow of
infected mice.
To assess the ability of activated cells that had already emigrated from the bone marrow,
we isolated cells from infected livers. Collagenase-perfused livers were harvested from both
BALB/c and B6 mice at 3.5 days after infection. Non-parenchymal cells, including PMN were
gradient-enriched and then kanamycin-resistant Lm were added. As shown in Fig. 4.7B, these
cells killed 30-40% of the added Lm. Together, these results suggest that there are no intrinsic
differences in the ability of PMN from susceptible BALB/c or resistant B6 mice to clear Lm
infection.

4.8 Discussion
To begin to address the possibility that susceptibility to listeriosis was determined by an
intrinsic defect in PMN function in mice, we developed an in vitro killing assay using PMN
enriched from murine bone marrow. We found that murine PMN killed opsonized Lm efficiently
even without being primed with agents such as PMA or IFNγ. Furthermore, murine PMN could
be sorted and kept in culture for at least 24 hours without affecting killing ability. We showed
that there was no intrinsic difference in the ability of BALB/c and B6 PMN to kill Lm directly ex
vivo. However, it is possible that in vivo, there are substances produced in the BALB/c liver that
inhibit the function of PMN and thus, contribute to the delayed clearance of Lm.
In agreement with previous studies using human PMN (67, 225), we showed that
opsonization with naïve serum significantly improved the ability of PMN to kill Lm. In vitro,
complement may be fixed on the surface of Lm through the classical or alternative pathway (67,
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68). In vivo, complement is rapidly activated during inflammation and may also be activated by
either proteases or acute-phase proteins present during infection (226). The concentration of
specific complement components in the liver during Lm infection is unknown, but several studies
have found increased expression of complement receptors on activated PMN (222-224). In
humans, specific antibodies may also be involved in enhancing uptake and killing of Lm. Using a
rabbit model, Vahidy et al. demonstrated that Lm opsonized with immune serum was internalized
to a significantly greater extent than bacteria treated with non-immune serum (227).
The ROS burst has long been thought of as a primary means by which PMN clear
microbes, through oxidative damage to bacterial DNA, peroxidation of membrane lipids, and
other mechanisms (216). ROS might also increase the K+ concentration in vacuoles, raising the
pH and releasing proteases from an anionic matrix to allow for optimal protease activity (228).
Assembly of the multicomponent NADPH oxidase is triggered by the act of phagocytosis,
resulting in targeted release of ROS (229, 230). However, in this study, only a high MOI induced
robust intracellular ROS production in PMN and increased ROS activity did not result in more
efficient killing of Lm. PMN from mice genetically unable to make ROS from birth had no defect
in killing Lm, therefore, non-oxidative killing mechanisms are sufficient. However, in animals
capable of triggering an ROS burst, modulation of that response led to reduced bacterial killing.
The loss of killing capacity observed after Tempol treatment was likely due to a disruption in the
ratio of available oxygen intermediates. Since Tempol has catalase-like activity and also acts as a
superoxide dismutase mimetic (219, 220), it presumably depletes the H2O2 that would normally
be acted upon by myeloperoxidase to form hypochlorous acid, the oxidizing agent for DHR 123
(215).
It is not surprising that Lm can be resistant to killing by oxidative mechanisms, as the
bacteria are known to produce both catalase and superoxide dismutase as protection against hostderived ROS (231). Previously, stationary phase Lm were found to be more vulnerable to killing
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by human PMN than logarithmic phase bacteria, a result that was attributed to lower catalase
production (232). Furthermore, superoxide dismutase was found to be phosphorylated and thus,
less active in stationary phase Lm (233). However, in our study, we found no significant
difference in the ability of murine PMN to kill either logarithmic phase or stationary phase Lm,
and both cultures produced similar bubbling reactions in the presence of hydrogen peroxide (Pitts,
unpublished observation). The Lm cytolysin LLO was also shown to inhibit the activation of
NADPH oxidase in macrophages (42); however, the toxin may be rapidly degraded in PMN
(234).
PMN granules contain a variety of proteins and peptides that provide non-oxidative
means of killing bacteria including cathepsin G, elastase, proteinase 3, lactoferrin, and lysozyme
(235). Alford et al. showed that purified cathepsin G alone could kill either S. aureus or Lm
(236). Since several of these compounds are serine proteases, (236, 237) we expected to find at
least a partial loss of killing efficiency after pretreatment with DFP, a serine protease inhibitor,
but this only occurred in a gp91phox-/- background. DFP was previously used to show that serine
proteases were important for human PMN to kill Streptococcus pneumoniae (238), but ROS
activity was not monitored in that study, so we cannot make a direct comparison to our results.
DFP was also used to inhibit proteolysis of CD43 on human PMN stimulated with opsonized
zymosan; in that study, the DFP did not inhibit ROS generation (221). This suggests that the
nature of the phagocytosed particle may determine whether or not DFP impacts the ROS burst.
Circulating PMN are readily obtained from human peripheral blood; however, the cells
are easily affected by ex vivo isolation and labeling techniques, and are prone to rapid cell death
(101, 239-241). In contrast, mature PMN harvested from the bone marrow have a longer half-life,
can be maintained in culture for at least 24 hours (114), and as we showed here, are not affected
by manipulations such as cell sorting. A key advantage of using unprimed cells, rather than cells
that have already egressed from the bone marrow, is the ability to study how specific
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inflammatory signals alter the functional properties of the PMN. An important challenge for
future work will be to understand how signals in infected tissues such as the liver may affect the
function of PMN during infection.

Figure 4.1 PMN recruitment to the liver following foodborne infection is similar in B6 and
BALB/c mice
PMN recruitment to the liver following foodborne infection is similar in B6 and BALB/c mice.
(A) Mice were fed 3 x 108 CFU of Lm SD2000. At 3 dpi, livers were perfused and total CFU
was determined. Total Ly6GhiLy6C+ PMN found in the non-parenchymal fraction after tissue
digestion in uninfected (NI) or infected (3 d) mice was also determined. Pooled results from
three independent experiments are shown. (B) Migration of gradient-enriched PMN toward 100
nM leukotriene B4 was monitored using an under-agarose assay. Representative results from
one of three independent experiments are shown (n=4 technical replicates per group).
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Figure 4.2 Murine PMN kill Lm efficiently in the presence of serum.
Gradient-enriched PMN were used to perform in vitro killing assays. (A) Representative dot plot
shows the composition of a typical gradient enriched bone marrow prep; live and single cell gates
were applied. (B) PMN (n=3 technical replicates) were incubated with Lm at a MOI of 0.05 for
90 min. Pooled results from 2 independent experiments are shown. (C) Lm were pre-treated as
indicated and added to PMN (MOI 0.1) for 60 min.

Representative results from one of three

independent experiments are shown. (D) Serum-opsonized Lm (MOI=2) was added to BALB/c
PMN. The absolute number of CFU remaining in the wells at either 1 h or 4 h for a representative
experiment is shown in the two left graphs. Dashed lines indicate the number of CFU at t=0. The
mean percentage killed at each timepoint (+/- SD) for three independent experiments is shown on
the right.
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Figure 4.3 Murine PMN rapidly internalize Lm in vitro.
Sorted murine PMN efficiently kill Lm. (A) Representative plots depict the three populations of
cells sorted from marrow of BALB/c (top row) and B6 (bottom row) mice. (B) Sorted cells were
plated in media for 1 h and then serum-opsonized Lm was added (MOI=0.1); killing efficiency
was assessed after 50 min. (C) Sorted cells were cultured overnight at 37°C in 7% CO2. The
following day, a killing assay was performed as described above. One of two independent
experiments with 3 technical replicates per group is shown.
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Figure 4.4 Murine PMN rapidly internalize Lm in vitro.
(A) Serum-opsonized Lm constitutively expressing GFP (Lm SD2710) was added to sorted PMN
(MOI=1) that were pre-treated for 45 min with either 20 μM cytochalasin D (cyto D) or DMSO
(vehicle). Cell-associated Lm were visualized by differential in/out staining 10 minutes post
infection. Representative images show intracellular (green) and extracellular (yellow) bacteria
(scale bar= 2 μM) and the mean percentage of internalized bacteria in three independent
experiments is shown. B) A representative killing assay performed at 50 minutes for cells treated
as in (A); bars indicate mean +/- SD. C) Gentamicin protection assay performed with serumopsonized Lm and gradient-enriched PMN (n=3 technical replicates) and incubated for 10 min
before addition of gentamicin. Gentamicin was added at t=0 as indicated by the arrowheads.
Data from two independent experiments (Exp 1, Exp 2) are shown.
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Figure 4.5 Lm induces a dose-dependent ROS burst in murine PMN.
Gradient-enriched PMN suspended in HBSS were incubated with dihydrorhodamine 123 prior
to the addition of Lm at MOI=4 (red), MOI=40 (blue); mock infected cells are shown in grey.
(A) Representative histograms for cells harvested 30 min after addition of bacteria and total
ROS+ Ly6GhiLy6C+ PMN are shown. (B) Gradient-enriched PMN were used for an in vitro
killing assay (MOI=10). Killing efficiency was assessed after 50 min. Representative results
from one of three experiments using n=3-5 technical replicates per treatment are shown. Bars
indicate mean +/- SD.
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Figure 4.6 ROS is not required for efficient in vitro killing of Lm.
(A) Gradient-enriched PMN from gp91phox-/- and B6 mice were loaded with DHR prior to addition
of either serum-opsonized Lm or 20 nM PMA. ROS levels were determined at 30 min and a
killing assay as performed at 50 min. Pooled data from two independent experiments are shown;
horizontal bars indicate mean +/- SD (B). Gradient-enriched PMN were incubated with 50 μM
Tempol or vehicle for 90 min. prior to addition of Lm and the percentage of ROShi neutrophils
and the killing efficiency for these cells was determined. Data from one of three independent
experiments is shown; bars indicate mean +/- SD. (C) Gradient-enriched BALB/c PMN were
incubated with DFP for 30 min. at the indicated concentrations prior to addition of Lm (MOI=10).
ROS activity was determined 30 min later and % killed was determined 50 min after addition of
bacteria (n=5). Representative results from one of two independent experiments are shown. Solid
grey histogram indicates uninfected. (G) Gradient-enriched PMN from gp91phox-/- males were
treated with DFP at the indicated concentrations for 30 min. prior to addition of Lm (MOI=10) for
an in vitro killing assay. Bars indicate mean for n=6 replicates from one of two independent
experiments
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Figure 4.7 Neutrophils harvested from the bone marrow of infected BALB and B6 mice kill
Lm with similar efficiency.
(A) CD11b surface expression on sorted PMN from uninfected mice (NI) or mice fed 3 x 108
CFU Lm SD2000 (2 dpi) was determined. Representative flow cytometry histograms are shown.
PMN were incubated with Lm SD2001 for 50 min and the percentage of kanamycin-resistant
bacteria killed was determined. Bars indicate mean +/- SD for 6 technical replicates from one of
three independent experiments. (B) BALB/c and B6 female mice were fed 1 x 109 CFU L.
monocytogenes and livers were harvested at 3.5 dpi following collagenase perfusion via the portal
vein. The enriched non-parenchymal fraction was plated and exposed to Lm SD2001 at the
indicated MOI for 50 min and the percentage of kanamycin-resistant bacteria killed was
determined. Bars indicate mean +/- SD for 6 technical replicates from one of two independent
experiments.

Copyright © Michelle G. Pitts 2018
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5. Prostaglandin E2 is a negative regulator of the neutrophil response to Listeria
monocytogenes
Pitts, MG and D’Orazio, SEF

Summary
During acute Listeria monocytogenes (Lm) infection, neutrophils (PMN) rapidly infiltrate
the liver and begin to remove both free bacteria and infected cells. In the C57BL/6J (B6) mouse,
hepatic Lm burdens quickly peak and then begin to decline, but in susceptible BALB/cBy/J
(BALB) mice the bacterial load continues to increase exponentially despite adequate PMN
recruitment. We previously showed that bone marrow PMN from both mice killed Lm with
similar efficiency.

This suggests that the microenvironment in the BALB liver may be

modulating PMN function.

Prostaglandin E2 (PGE2), an immunomodulatory lipid previously

shown to suppress Th2 responses and PMN effector functions, was produced in significantly
higher amounts by the mononuclear leukocyte fraction of cells from infected BALB livers than
cells from infected B6 livers. PGE2 significantly inhibited in vitro killing of Lm by both B6 and
BALB PMN, and this loss of function was rescued by PGE2 receptor antagonism. We previously
found that PMN isolated from mice lacking the gp91 subunit of NADPH oxidase efficiently
killed Lm within 50 minutes. When these PMN were treated with PGE2, however, no loss in
killing was observed, suggesting that PGE2 was impacting oxidative killing mechanisms. Data
also suggests that the presence of PGE2 negatively affects PMN migration and internalization of
Lm, thus affecting production of reactive oxygen species and overall killing efficiency. Thus, an
excess of PGE2 secretion in the infected BALB liver negatively impacts PMN ability to kill Lm
by blunting multiple killing mechanisms, allowing the bacteria to replicate exponentially during
critical early stages of the infection.
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Introduction
Prostaglandin E2 (PGE2) is a signaling lipid derived by enzymatic modification of
arachidonic acid present in the cell membrane. Related compounds, called eicosanoids, include
leukotriene B4 (LTB4), thromboxane A4, and prostacyclins. PGE2 is probably best known for its
roles in pain and fever; in fact, it is a classic pro-inflammatory mediator with numerous drugs
directed at its production. However, there is a growing body of knowledge related to the role of
PGE2 in inhibition of innate immune responses, such as aberrant T cell polarization, inhibition of
macrophage function, induction of IL-10 secretion, and suppression of PMN effector functions
(148-155). The role of PGE2 in the body seems to depend strongly on the tissue, the stimulus
causing its induction, and the timing of secretion. In many situations, suppression of innate
immunity by PGE2 may outweigh its induction of pro-inflammatory pathways.
Introduction of mechanical trauma or inflammatory stimuli such as bacteria can stimulate
production of PGE2, which begins with release of arachidonic acid from the cell membrane by
one of three phospholipase A2 enzymes. Two of these, cPLA2 and sPLA2, are inducible, and
cPLA2 has been shown to be activated by secretion of the cholesterol-dependent cytolysin LLO
(157). Once arachidonic acid is liberated, it may be oxidized by the cyclooxygenase enzymes
(COX-1 and COX-2), producing an intermediate prostaglandin that is further enzymatically
modified by prostaglandin E synthase (PGES) to produce PGE2. Three isoforms of PGES existmicrosomal PGES (mPGES) 1 and 2 and cytosolic PGES (cPGES).

A study using peritoneal

macrophages of BALB/c and B6 mice found that BALB/c macrophages express higher levels of
mPGES and thus produce more PGE2 when stimulated with LPS (150). Free arachidonic acid
can also be metabolized by the lipoxygenase pathway, ultimately resulting in leukotrienes
including LTB4, a lipid with chemotactic properties for PMN (106, 107). Activation of 15lipoxygenase results in secretion of lipoxin A4 (LXA4), a pro-resolution lipid produced during the
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plateau phase of PMN swarming (109, 159, 160). Using human PMN, Levy et al. showed that
PGE2 exposure switched lipoxygenase activity from predominately 5-LO, producing LTB4, to
15-LO, making LXA4 within 5 hours (160). This study provided strong evidence that PGE2
could induce downregulation of the PMN inflammatory response.
PGE2 is rapidly removed from circulation and may also be degraded by a dehydrogenase
or by albumin (162-165). It binds four G-protein coupled receptors, designated EP1-EP4, which
are expressed on a variety of tissues and cells (152, 166, 167). Ligation of EP2 and EP4
stimulates an increase in cyclic adenosine monophosphate (cAMP) through activation of
adenylate cyclase (168), and it is ligation of these two receptors that is also thought to result in
many of the immunosuppressive effects of PGE2 (152, 162).
Numerous studies examining the effect of PGE2 on innate immune functions have
concluded that, given the necessary stimulation and environment, it is an immunosuppressive
compound (152, 156, 162). More than thirty years ago, Hutchison and Myers identified PGE2 in
splenocyte culture supernatants as a factor that suppressed peritoneal macrophage phagocytosis of
Lm (177). Since then, PGE2 has been observed to be produced at higher levels by stimulated
BALB cells than B6 cells and additionally, BALB mice were found to be more sensitive to its
effects than were B6 mice (149, 150). PGE2 is also a potent inhibitor of production of reactive
oxygen species and secretion of IL-12 and TNFα from monocytes (151, 153, 242), all of which
could have impacts on the course of Lm infection.
Following foodborne infection, PMN are robustly recruited to sites of Lm colonization
including the liver (75, 147, 243). PMN are thought to be necessary for removal of Lm from the
liver, where they may both lyse infected hepatocytes as well as kill free bacteria (62, 89, 90). We
previously showed that bone marrow PMN from susceptible BALB and resistant B6 mice killed
Lm with similar efficiency in vitro, suggesting that any inhibition of PMN function in the liver
was an effect of the microenvironment (243). In this study, we show that PGE2 causes a dose84

dependent decrease in PMN killing efficiency in vitro, and that PGE2 is produced at higher levels
by immune cells harvested from the livers of Lm-susceptible BALB mice than cells from resistant
B6 mice. These data suggest that PGE2 and its family of eicosanoids should be more closely
examined as immune modulators as more is learned about the course of dissemination and growth
of Lm following foodborne infection.

5.1 Lm exposure induces upregulation of COX-2 in myeloid cells in vitro
COX-1, thought of as a “housekeeping” enzyme, and COX-2, the inducible
cyclooxygenase enzyme, are the first enzymes that act on arachidonic acid to produce
prostaglandins once it has been liberated from the cell membrane.

Although reports are

somewhat contradictory on the levels of COX-2 at basal levels, this enzyme is considered to be
induced by inflammatory stimulation (158, 162). To measure Lm-mediated stimulation of PGE2
production in myeloid cells, bone marrow-derived monocyte cultures were stimulated with live
Lm SD2000. Three populations of cells were present, Ly6Chi monocytes, Ly6C-CD64+
macrophages, and a transitioning CD64hiLy6Clo/med population (Fig. 5.1A). As shown in Fig.
5.1B, COX-2 was expressed in all three populations prior to stimulation. When cells were
exposed to heat-killed sonicated Lm or infected with live, replicating Lm, both the MFI and the
COX-2+ percentage of each cell type increased. However a lower percentage of monocytes
(GR1+CD64_) was COX-2+ prior to treatment and these cells responded at a lower level to
stimulation than macrophages or transitioning cells.

5.2 Lm infection induces PGE2 secretion in the livers of BALB/c mice
Since monocytes and PMN infiltrate the liver within three days after foodborne infection
(Fig. 5.2A, (243)), we next decided to assess COX-2 expression levels in cells harvested from the
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livers of infected mice. At three days after infection, a mixed population of cells was harvested
from the livers of BALB and B6 mice and enriched for hematopoietic cells using gradient
centrifugation. These cells were stained for intracellular COX-2 expression as well as surface
markers for PMN, monocytes, Kupffer cells, and B and T lymphocytes. As shown in Fig. 5.2B,
however, intracellular staining for this enzyme did not reveal any conclusive infection-related
induction of COX-2, and furthermore did not point to any one cell type as the primary producers
of PGE2 in response to Lm.
PGE2 is often a locally-acting compound and has both autocrine and paracrine functions
(156).

Additionally, it is metabolized very rapidly, making ex vivo measurement in a mixed

population of cells difficult (163, 164).

In order to measure PGE2 in the liver, a proxy

measurement, prostaglandin E2 metabolite (PGEM) was used. PGEM is a stable converted
metabolite of PGE2 useful for determining PGE2 secretion in situations where PGE2 is secreted
but also metabolized by neighboring cells. First, mice were fed Lm and livers were harvested at 3
dpi and homogenized. When clarified supernatants from liver homogenates were tested, PGEM
measurements were low and variable (Fig 5.2C). Because of this, we next depleted parenchymal
cells from collagenase-digested livers and cultured the remaining hematopoetic fraction
overnight, allowing secretion of PGE2 into the supernatant.

A mixed population of non-

parenchymal cells was isolated from the livers of infected animals to assess PGE2 secretion
following in vivo infection. As shown in Fig. 5.2A, this population consisted of neutrophils,
monocytes, and numerous other cells not stained by Ly6G and Ly6C markers. Cells from
infected BALB/c livers, which contained an average of 10-15-fold higher CFU burdens than B6
livers (Fig. 5.2D), secreted significantly more PGE2 in overnight culture than cells from infected
B6 livers (Fig. 5.2E). To address concerns that perhaps the high CFU burden in BALB liver
cultures was driving PGE2 secretion and understand what stimulus initiated secretion, uninfected
liver cells were exposed to live Lm or heat killed, sonicated Lm. For comparison, cells from
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infected mice were further stimulated with heat killed, sonicated Lm. As shown in Fig. 5.2F, the
additional stimulation boosted PGE2 secretion from cells obtained from infected livers; however,
only cells from infected mice were capable of secreting PGE2 under any of the conditions tested.
Thus, in vivo conditions in the BALB/c liver initiated PGE2 secretion and that secretion could be
increased by further stimulation.
To assess whether the effects of augmented PGE2 signaling or inhibition could be seen
on a macroscopic level, mice were treated with either indomethacin, a COX-2 inhibitor, or
exogenous 16,16 DM PGE2, a receptor agonist, after infection. However, neither of these
treatments had a clear effect on CFU burdens in the liver or spleen at 3 or 4 dpi (Figure 5.2G and
H). Interestingly, BALB/c mice receiving indomethacin treatment appeared more active and less
ruffled than mice receiving vehicle treatment. PGE2 treatment seemed to have no gross effect on
the behavior or appearance of B6 mice, however.

5.3 PGE2 down-regulates PMN killing efficiency through EP2 and EP4 signaling
PGE2 was previously shown to modulate many functions of innate immunity, including
macrophage phagocytosis and PMN ROS burst and TNFα secretion (153, 171, 179). It followed,
therefore, that overproduction of PGE2 could play a role in the growth of Lm observed in
BALB/c livers.

All of the above-mentioned effects are indirect measures of cell function,

however. To directly test the effect of PGE2 on the ability of PMN to kill Lm, an in vitro killing
assay using bone marrow PMN was used as previously described ((243), chapter 4). Gradient
enriched bone marrow PMN were plated in tissue culture media and then treated with PGE2 for
30 or 90 min., as indicated, before addition of Lm. As shown in Fig. 5.3A, PGE2 treatment
yielded a dose-dependent reduction in killing efficiency as compared to vehicle treatment. The
highest amounts of inhibition were observed at 1μM after 30 min. of treatment or .1-1 μM after
90 min. of treatment. Wells in which PMN were treated with PGE2 yielded 33-50% more
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bacteria than vehicle-treated wells. As shown in Fig. 5.3B, when the average reduction in killing
with 1 μM PGE2 was pooled across many samples, similar results were observed with both
BALB and B6 PMN despite variability from assay-to-assay.
Two of the four PGE2 receptors, EP2 and EP4, have previously been shown to be
responsible for most of the immune-inhibitory actions of PGE2 signaling (168, 171, 172, 179,
180). Much of this is thought to be a result of intracellular cAMP accumulation; however, little is
actually known about how cAMP accumulation affects the direct killing ability of phagocytic
cells. To assess the contribution of these two receptors to the PGE2-dependent loss of killing,
PMN from BALB/c and B6 mice were treated with EP2 and EP4 receptor antagonists
concurrently with PGE2.

As shown in Fig. 5.3C, PGE2 caused a 20-30% loss of killing

efficiency. EP2 antagonism partially rescued this loss of killing, with further rescue observed
using EP4 antagonism. Although some variation was again present, nearly full rescue was
observed in many samples. These results suggested that the inhibition of PMN killing caused by
PGE2 was dependent on the EP2 and EP4 receptors.

5.4 PGE2 exerts pleiotropic effects on PMN function
EP2 and EP4 ligation mediate an increase in cAMP that was previously shown in murine
PMN to result in decreased secretion of TNFα after LPS stimulation (171). Other EP2 and EP4dependent effects have also been shown in macrophages, including lower phagocytosis efficiency
and reduced ROS burst (151, 178). We previously showed that mouse PMN kill Lm through
redundant oxidative and non-oxidative mechanisms (chapter 4), but how these receptors influence
the many mechanisms that PMN use to kill, however, is unknown. Since reductions in killing
efficiency after PGE2 treatment averaged 20-30%, we reasoned that there were likely to be
several small testable effects within the parameters of using bone marrow PMN that added up to
the larger phenotype.
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An under-agarose assay was first employed to assess the effect of PGE2 treatment on
PMN chemotaxis toward a 1000 nM LTB4 gradient. Enriched bone marrow PMN from BALB/c
and B6 mice were suspended in media containing 1 μM PGE2, incubated for 5 min., and added to
the assay gel. After 2 hours, maximum distance traveled under the agarose was measured. As
shown in Fig. 5.4A, untreated cells traveled 19-35% farther than cells treated with PGE2.
Because deficiencies in chemotaxis could result in lower bacterial internalization, in/out staining
after PGE2 pre-treatment was next used to assess the efficiency of phagocytosis. To obtain a
pure population of PMN to study, cells were sorted using Ly6G and Ly6C markers. GFPexpressing bacteria were added to PMN that had been pretreated with PGE2, and in/out staining
was performed at 10 mpi, a point at which it was already known that most cell-associated bacteria
could be found intracellularly ((243), chapter 4). At this point, approximately 10-12% fewer cellassociated bacteria were found to be intracellular when cells were PGE2-treated (Fig 5.4B).
Since internalization of bacteria in PMN results in ROS generation, we next used Mcherry expressing Lm together with dihydrorhodamine (DHR), which is oxidized to rhodamine
and fluoresces comparably to FITC in the presence of ROS. Treatment of cells with 1μM PGE2
prior to addition of bacteria caused a 5-7% reduction in the percentage of cells detected to contain
M-cherry bacteria and a comparable reduction in ROS positivity at the same time point (Fig.
5.4C). Importantly, however, further assays to detect reductions in ROS due to PGE2 exposure
were unsuccessful. It is difficult to say whether reagent breakdown or compensation of the colors
led to the differences. The initial experiment, however, was performed using sorted cells and
subsequent experiments used gradient-enriched cells with surface staining after exposure to
bacteria and DHR. Other than incidental mouse-to-mouse variation, it seems likely that the
differences in the particular parameters of the initial experiment vs subsequent experiments led to
the lack of positive results from the latter.
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We previously showed that gp91phox-/- PMN had no defect in killing Lm despite
complete lack of ROS burst ((243), chapter 4). Furthermore, the data in chapter 4 suggested that
ROS in wild type mice, a reduction in ROS could result in a small but significant reduction in
killing efficiency. To understand if the effect of PGE2 on ROS extended beyond the initial 10minute time point and affected killing efficiency, gp91phox-/- PMN were incubated in 1 μM PGE2
for 90 min before addition of Lm. As shown in Fig. 5.4D, PGE2 pretreatment resulted in an
approximate 15% decrease in wild type PMN killing efficiency but had no effect on the ROSdeficient PMN, indicating that it indeed was affecting ROS in the wild type cells. Together, these
data suggest that PGE2 has numerous small effects on the multiple methods that PMN use to kill
Lm.

5.5 Discussion
PMN are recruited to Lm-infected liver and thought to be necessary for hepatic clearance
of Lm, yet the connection of PMN killing efficiency to susceptibility in listeriosis has not been
previously explored.

Our lab previously showed that bone marrow PMN from susceptible

BALB/c and resistant B6 mice killed Lm with similar efficiency, indicating that upon egress from
the marrow, these cells were likely to be in a similar state of readiness and suggesting that in the
liver, they encounter an environment that changes their functional capacities. In this study, we
examine the effects of PGE2, an immunomodulatory lipid, and show that it is both produced at
higher levels in the livers of susceptible animals and that PMN are less able to kill Lm in its
presence.
It was not surprising to find PGE2 produced by fractionated BALB liver immune cells;
however, it was unexpected to find that infection appeared not to induce PGE2 secretion in
samples from B6 mice. Whether this was due to a differential cell infiltrate at 3 dpi is unknown.
Previous studies using macrophages have indicated that BALB cells possess more PGE2 binding
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sites and produce more PGE2 after stimulation than B6 or C3H/HeN macrophages (149, 150), but
to the best of our knowledge this is the first study to find differential secretion in the context of
infection.

Unfortunately, we were unable to verify induction of COX-2 in response to in vivo

infection. However, two explanations exist for this. First, a low percentage of total cells are
likely to be infected at any given time in the liver after foodborne transmission. It seems likely
that COX-2 induction and/or PGE2 secretion are dependent on the presence of bacteria in
neighboring cells, if not within the producing cell itself. Furthermore, the extensive processing
required to fractionate immune cells from the liver could easily negatively impact this staining.
The impact of PGE2 pretreatment on the ability of PMN to kill Lm was, on average, a 2030% loss of killing efficiency.

This means that in comparison with vehicle-treated cells,

approximately 25% more bacteria escaped killing, remaining alive and able to replicate after 50
min of contact with PMN. Since PMN are likely to accumulate in the liver over the course of
several days after foodborne infection and be exposed to tonic as well as acute PGE2 secretion,
these results are suggestive that the in vitro phenotype could also be observed in vivo. Levy et al.
proposed the idea of an “eicosanoid switch,” a process by which PMN are exposed to PGE2 for
several hours and then begin to modulate their own dispersal by producing pro-resolution lipoxin
A4 (160). These results were supported by the recent work of Reategui et al. in which swarming
PMN produced lipoxin A4 during the plateau phase of the swarm, thus changing their behavior
pattern (109).
Many of these results are supportive of results others have obtained using other cell types
and other forms of stimulation after PGE2 treatment.

The small but significant effects on

chemotaxis, bacterial internalization, and ROS are also supportive of the larger phenotype, a
defect in overall killing capacity in PMN. Together, these results point to an immunomodulatory
role for PGE2 during the context of bacterial infection that could easily play a part in other
opportunistic infections. Further work with the foodborne infection model and refinement of
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techniques to measure PGE2 in the infected host will be required to elucidate the effects of PGE2
on clearance of Lm.

Figure 5.1 In vitro infection induces COX-2 upregulation
Bone marrow-derived monocytes (GR1+CD64-), transitioning cells (GR1+CD64+), and
macrophages (CD64+GR1-) were infected for 2 hr with Lm SD2000 (MOI=1) for 2 hr
followed by addition of 25μg/ mL gentamicin.

COX-2 expression was assessed after

overnight incubation. (A) A representative plot depicts the three cell types in culture at day
four. On the right, a representative COX-2 histogram for transitioning cells is shown with
uninfected cells on the left and infected cells on the right.

(B) Percent COX-2+ cells for

each cell type and COX-2 mean fluorescence intensity (MFI) and are shown. Pooled results
from three independent experiments are shown; bars indicate mean +/- SD.
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Figure 5.2 In vivo Lm infection stimulates PGE2 secretion from liver non-parenchymal cells
BALB and B6 female mice were fed 5 x 108 CFU Lm SD2000 and livers were harvested 3 dpi
following collagenase perfusion. (A) Left- Monocyte infiltrate in the livers of uninfected (-) or
infected (+) mice. Each symbol represents one mouse; three pooled experiments are shown.
Right- an example of a typical FACS profile of liver non-parenchymal cells is shown. Live,
singlet, and CD45+ gates were incorporated prior to applying Ly6G and Ly6C gating. (B) Liver
non-parenchymal cells were harvested from infected mice and stained for markers of B and T
lymphocytes, PMN, monocytes, and Kupffer cells (KC). COX-2 median fluorescence intensity is
shown as change compared to uninfected cells. Each symbol represents one mouse; three pooled
experiments are shown. (C) Prostaglandin E Metabolite (PGEM) was measured from supernatant
of clarified BALB liver homogenates. Pooled results from two experiments are shown. (D, E)
Livers were harvested from infected mice after perfusion and collagenase digestion. CFU burden
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was determined from a portion of cells prior to depletion of hepatocytes (D) and the remainder
was cultured overnight at 37°C in 7% CO2 for determination of secreted PGE2 (E). Pooled
results from three independent experiments; n=1-2 mice per repeat are shown.

(F) Non-

parenchymal cells from uninfected or infected BALB livers were stimulated by exposure to heatkilled, sonicated Lm or infected in vitro. (G) BALB females were treated with indomethacin
every 12h beginning 24 hpi. Organs and blood were harvested at 72 hpi. (H) Female B6 mice
were treated with 16,16 dmPGE2 once daily beginning immediately after infection and organs
were harvested at 4 dpi. Results from one experiment are shown, bars indicate mean +/- SD.
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Figure 5.3 PGE2 pretreatment results in a dose-dependent loss of killing efficiency in
murine PMN
(A) BALB/c and B6 PMN were incubated with the indicated concentrations of PGE2 for 30 or 90
min. before 50 min incubation with Lm (MOI=1). Representative results; n=4 replicates per
treatment, are shown. Bars indicate mean +/- SD. Below this, the number of CFU per well are
shown for one representative experiment in which Lm (MOI=1 or 10) were either incubated for
50 min alone to measure growth, with PMN that had received vehicle treatment, or with PMN
that were pretreated with 1μM PGE2. Dotted line indicates initial inoculum. Representative
results are shown for one of two independent experiments; n=5 technical replicates per treatment,
bars indicate mean +/- SD. (B) Pooled results are shown for experiments where PMN were
incubated with 1 μM PGE2 for 60-90 min. Each symbol represents the mean for one experiment.
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(C) (Top) BALB and B6 PMN were incubated with 1 uM PGE2 concurrently with 100 nM EP-2
antagonist PF-04418948 or EP4-antagonist L-161,982 prior to addition of Lm (MOI=1).
Representative results for a killing assay are shown; n=3 technical replicates per treatment. Bars
indicate mean +/- SD. (Bottom) Pooled, normalized results for three independent experiments
with three technical replicates per treatment are shown. Each symbol represents the mean of one
experiment.
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Figure 5.4 PGE2 exerts pleiotropic effects on PMN function
(A) Gradient enriched PMN were suspended in media containing 1 uM PGE2, incubated for 5
min, and applied to an under-agarose assay with 1000 nM LTB4 as the attractant in a well that
was 1mM away from the wells containing cells. Results from one experiment are shown; n= 4
technical replicates per treatment. (B) FACS-sorted BALB/c PMN were incubated in 1 μM
PGE2 for 90 min prior to addition of Lm SD2710. Percent of cell-associated bacteria at 10 mpi
found intracellularly using in/out staining is shown. Results from one experiment are shown; n=3
technical replicates per treatment. (C) FACS-sorted PMN were incubated in 1 μM PGE2 for 90
min prior to addition of DHR and M-cherry expressing Lm. Percent of PMN positive for Mcherry at 10 and 30 mpi is shown on the left, and percent of ROS+ cells is shown on the right.
Representative results for one of two experiments are shown (D) Bone marrow PMN from B6
and gp91phox-/- mice were sorted, exposed to 1 μM PGE2 for 90 min, and then incubated with
Lm. Percent of inoculum killed at 50 mpi is shown; n=5 technical replicates per treatment,
representative results from one of two experiments. In all cases, bars indicate mean +/- SD.
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6.

Discussion, conclusions, and future directions
Listeriosis in humans is lethal in approximately 25% of all diagnosed cases (12, 13), yet

surprisingly little is known about its natural course of infection. Some of this is due to listeriosis
being a relatively “new” recognized disease. In fact, although the bacterium was described in
1926 (244) and there were periodic outbreaks of illness attributed to foodstuffs, research on Lm as
a serious human pathogen did not begin until the mid-1980s.

For years, however, Lm was used

as a tool for immunology discovery rather than studied as an important foodborne pathogen. Lm
has been considered a model intracellular pathogen for years, and intravenous infection of mice
with Lm has yielded results that are now pillars of immunology and pathogenesis knowledge.
Much of what we now know regarding how intracellular bacteria invade cells and escape
phagosomal killing, as well as the necessity of IFNγ for clearance of intracellular bacteria can be
attributed to use of Lm.
Intravenous infection has also been a method used to skirt the problem that mice are not a
natural host for Lm. Doses in excess of 1010 Lm could be given to wild type mice via gavage with
no impact on survival (29), while significantly lower doses of ~103-104 bacteria were required to
observe liver and spleen invasion and even rapid death using intravenous inoculation (46, 212)
This was because of a single amino acid mismatch between a key virulence determinant needed
for entry of non-phagocytic cells, InlA, and E-cadherin, its receptor on enterocytes (30). To
improve the efficiency of murine infection by the oral route, Lecuit et al. created a “humanized”
mouse expressing enterocyte-restricted human E-cadherin (29) and later Wollert et al. created a
“murinized” version of InlA, termed “InlAm” (58). These groups and many others, however, still
used gavage, a sometimes-traumatic method by which bacteria are delivered directly to the
stomach, for infections. When Bou Ghanem et al. later developed a method of foodborne
transmission of Lm in mice, InlA was not found to be required to establish intestinal infection, but
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InlAm enhanced persistence in the underlying intestinal tissue and spread to the mesenteric lymph
nodes (35).
Still, however, little of the pathway from the stomach to the intestinal lamina propria to
the extra-intestinal organs has been explained. Melton-Witt et al. orally infected guinea pigs with
tagged Lm clones and used mathematical modeling to conclude that only approximately 1 in 106
Lm will invade the intestinal epithelium (72). Becattini et al. recently showed that in mice with a
healthy microbiota, Lm was significantly less able to invade and disseminate to other organs than
in mice which had received antibiotic treatment, indicating an important role for intestinal
microbiota and their products in protection against pathogenic bacteria (181). These data indicate
that very low numbers of Lm will be able to successfully pass through the cadre of immune cells
waiting in the lamina propria and subsequently be transported to the liver and spleen. Despite
encountering multiple barriers to invasion and dissemination bottlenecks, Lm causes very serious
disease when it overcomes initial barriers. Thus, it is important to understand how dissemination
occurs and the host immune responses that occur at each step of the pathway.
The area that I chose to focus on for my dissertation work was host immune responses,
first in the spleen and then in the liver. Much is known about how intravenously inoculated Lm
are taken up by the liver and spleen (64, 76, 78), but relatively little has been determined
regarding the immune responses that are triggered when (presumably) small numbers of stressadapted bacteria arrive to these organs after foodborne infection. Apart from the clear necessity
for IFNγ for Lm clearance, even less is known about what local and systemic mediators are
induced by dissemination of foodborne bacteria and how these mediators influence the course of
infection. Some of these mediators can have opposing effects depending on their timing, tissue,
and stimulus, which could be important as a pathogen like Lm moves slowly out of the intestine
and into the peripheral organs. Therefore, chose to examine type I IFN and PGE2, two mediators
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more classically-known as pro-inflammatory but which had previously been shown to have antiinflammatory roles in certain tissues and environments.
Initially, I focused on the “type I IFN response” to Lm in the spleen, a phenotype that
was first observed when IFNAR1-/- mice were found to be more resistant to intravenous Lm
infection than their wild type counterparts (142, 143, 145).

Later however, another group

concluded that type I IFN signaling was necessary for defense against Lm infection after
intragastric inoculation of Lm LO28, a strain that causes hyper-induction of IFNβ secretion (126,
189).

Much of the resistance phenotype found after i.v. infection was attributed to IFNα/β-

dependent downregulation of IFNγR1, which was thought to decrease macrophage activation
(83). The results presented in chapter three, however, suggest that type I IFN is inconsequential
in the course of foodborne listeriosis. This work showed that IFNAR1-/- mice were not resistant to
foodborne Lm infection in comparison to wild type B6 controls and that little, if any, type I IFN
was produced in the spleen after foodborne infection. Importantly, this work also showed that
downregulation of the IFNγ receptor was a consequence of infection, rather than a consequence
of type I IFN signaling. It seems likely that during the course of infection, IFNγ is naturally
secreted and the receptor is simply internalized after binding its ligand. It is undisputed that type
I IFN can cause downregulation of IFNGR1; however, this appears to only be of importance in
high dose experimental i.v. infection thus far.
Overall, the results shown in chapter three indicate that while type I IFN can play an
important role in the pathogenesis of Lm infection, its induction is strongly dependent on the
route of infection. If work in the Listeria field were to move forward with type I IFN, it seems
reasonable to ask if type I IFN is routinely found in samples from positively diagnosed patients.
IFNα/β secretion is a part of innate immunity, however, meaning that it is produced early in the
course of infection, therefore finding it in patients days to weeks after consumption of
contaminated foods could prove difficult. The most relevant scenario might actually be maternal-
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fetal transmission, which occurs via the bloodstream or invasion of the placenta. Interestingly,
Cappelletti et al. recently found that stimulation of type I IFN signaling in pregnant mice induced
preterm birth (245), suggesting that a pathogen that invades the placenta and causes robust
IFNα/β signaling could be the cause of some miscarriages and spontaneous abortions.
PGE2 is a lipid mediator well-known for its roles in pain and fever; however emerging
evidence has pointed to PGE2 as an anti-inflammatory compound in certain settings (152, 153,
162). I hypothesized that PGE2 played an anti-inflammatory role in the liver after foodborne
infection by blunting the effector functions of PMN, which are recruited to the liver after
infection and necessary for Lm clearance (53, 91, 93, 94). In turn, this lack of bacterial killing in
the early phase of Lm colonization of the liver contributed significantly to the susceptibility
observed in BALB mice, particularly in the liver. In order to understand how PGE2 affected
PMN in the context of infection, it was necessary to first understand how PMN interacted with
and killed Lm. This provided an opportunity to study PMN from both Listeria-susceptible BALB
mice and resistant B6 mice and to determine if any key differences existed between PMN from
these two strains. Most differences in susceptibility to intracellular bacteria between these two
strains have been attributed to facets of innate immunity including differential secretion of IFNγ
(48-50), yet the ability of PMN to directly kill Lm had not been examined. I hypothesized that
PMN from both mice would kill Lm similarly, but that BALB PMN encountered a suppressive
microenvironment in the liver, thus blunting their normally highly bactericidal effector functions.
Mouse PMN are not routinely used in studies of bacteria-PMN interactions, both because PMN
are easily obtained from human blood samples as well as because of perceived differences
between murine and human PMN. The results shown in chapter 4 suggest that for pathogens
which elicit a strong PMN response such as Francisella tularensis and Streptococcus pyogenes,
studies using mouse bone marrow PMN would provide useful information on how these
pathogens are killed by or evade PMN killing. In particular, Francisella tularensis, another
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intracellular pathogen, elicits a robust PMN response to the lungs but is also one of the few
pathogens known to parasitize PMN (for a review, see Allen, L.A. 2016, Frontiers in Cellular
and Infection Microbiology).

The Francisella field has also undergone some of the same

evolution of knowledge regarding the necessity for PMN in early clearance as Listeria has. With
the knowledge that mouse bone marrow PMN are relatively long-lived an amenable to sorting
and other manipulations, it would be worthwhile to understand how the functional “age” (i.e.
relatively young bone marrow PMN vs “older” circulating PMN) and activation markers affect
this unusual phenotype.
With regard to continuing this research line with Listeria, the possibilities are almost
endless. Understanding how the tissue microenvironment affects PMN expression of homing
markers CXCR1, CXCR2, receptors for leukotriene B4, and the formyl peptide receptors should
be of foremost importance, as PMN are needed for clearance but also contribute to tissue damage
in listeriosis. The under-agarose assay is a crude measure of chemotaxis, and other, more
sophisticated methods should be considered including simple microfluidic assays. Although it
provided a useful measure of movement, the under-agarose assay lacks the ability to control for
the weight of the agarose or small variations in the thickness and purity of the agarose that could
impede movement.

I was also unable to verify Listeria-specific chemotaxis, as the

chemoattractant used in these assays must be able to rapidly diffuse into the agarose to create a
concentration gradient. Use of purified liver PMN rather than bone marrow PMN to assess
chemotaxis would also improve the physiological relevance of this data; however, this will
require a method to cleanly extract PMN from the liver, however, without inadvertently providing
activation or apoptosis signals.
Although it provided the data necessary to answer the question at hand, Figure 4.4 also
raises some interesting questions also that should be answered in the future. In Figure 4.4C, a
very small percentage of inoculated bacteria are intracellular at 25 mpi. This in itself is not
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impressive, as PMN are likely to initiate killing mechanisms nearly as soon as the phagocytic
vacuole closes, thus most of the bacteria phagocytosed early were already degraded. The time
points after this, though, show that the number of intracellular bacteria remains low but steady,
suggesting some level of survival inside PMN. Importantly, however, the cells used in these two
assays were gradient-enriched, meaning that a significant percentage of the cells were not PMN
and could potentially allow Lm to exist or grow. A follow-up experiment to this should include
sorted PMN and time points of 15 min-2 hr after inoculation.
The role of PGE2 in Lm pathogenesis is potentially far more complex than that of type I
IFN and is something that should be further explored. Even as it plays important roles in
regulation of blood pressure, kidney function, and induction of IL-6 (173, 174, 246), PGE2 could
be playing a pathogenic role in the progression of listeriosis. Most study of the effects of PGE2
has dealt with isolated capabilities of phagocytes, such as showing decreased phagocytosis, or a
reduction in TNFα secretion (153, 177). Here, I attempted to look at the whole picture and
hypothesized that PGE2 was secreted at high levels in the BALB liver after infection and was
thereby able to decrease the killing efficiency of PMN recruited to this site of infection. A
cartoon depicting the overall hypothesis for this research is depicted in Fig. 6.1. PMN are
primary effector cells in a variety of situations, including listeriosis, tularemia, candidiasis, and
even cuts and scrapes. If PMN exit the bone marrow able to effectively neutralize virulent
bacteria, and then encounter a microenvironment that downregulates that ability to kill before
they have done their job, it is almost certain that this decreased capability will be apparent in
higher disease burdens. Likewise, PMN have to be controlled so as to prevent inadvertent tissue
damage as a result of their many methods of neutralizing bacteria. This could be of special
importance in cases of immune compromise, where eicosanoid secretion is likely to be
dysregulated already.
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I found that PGE2 was both produced at higher levels by liver cells from susceptible
BALB animals than from B6 animals and that PGE2 effectively down-modulated the killing
efficiency of unprimed bone marrow PMN. These results are supportive of numerous other
reports showing inhibition of cell functions such as phagocytosis in macrophages and decreased
production of ROS in PMN (153, 177), but to the best of my knowledge, this is the first report of
PGE2 exposure decreasing the ability of any cell to kill a pathogenic bacterium. The especially
intriguing part of these results, however, may be that PGE2 did not just have one effect on PMN.
Instead, these data suggest that PGE2 may modulate PMN motility, internalization of bacteria,
and production of reactive oxygen species. These may all represent a target for therapeutic
intervention in the liver and beyond as we look for ways to augment human immunity to disease
without the use of antibiotics.
This research could be taken in several different directions. The connection of PGE2
secretion to aging and susceptibility to listeriosis should be more fully explored in particular.
Experiments could include PMN behavior tracking using bone marrow from aged mice,
foodborne infection of aged mice, and blood samples from elderly human donors. Given the
known roles for PGE2 in aging and inflammation, I would hypothesize that PMN from elderly
samples are sensitive to the effects of PGE2 and are less able to migrate toward and kill bacteria
than PMN from young samples.
The best way to elucidate the effects of PGE2 on PMN function in the context of the liver
might actually be an adoptive transfer. PMN could be antibody depleted from BALB/c mice and
PMN from congenic mice adoptively transferred in at the time of infection. The time course of
foodborne infection along with PMN recruitment to the liver might present some challenges, but
performing this experiment using i.v infection would yield some context as to whether further
efforts should be undertaken to do the depletion for foodborne infection or not.
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The idea presented by Levy et al. of an “eicosanoid switch” (160) should also be
explored. Are PMN in the liver, in the presence of high levels of PGE2, induced to secrete
lipoxin A4, thus resulting in resolution of PMN swarming? Does “resolution” happen before it
should, or do B6 mice resolve PMN-mediated inflammation early on, thus alleviating the
prospect of tissue damage? A first step in these experiments would be to sort PMN and treat with
PGE2 for 6-8 hours before assessing killing ability. I would hypothesize that a very long
exposure to PGE2, possibly with “boosters” would result in severe down regulation of PMN
chemotaxis and killing, coinciding with increased transcription of 15-lipoxygenase. Following
this set of experiments, lipoxin A4 could be measured by EIA and also added exogenously.
Much of the immune response to foodborne bacteria remains underexplored. Overall, the
results presented in these chapters suggest that immune mediators during foodborne infection can
have very different roles given unique stimuli, tissue environments, and timing. More so than any
other infection route, infections acquired from consumption of contaminated foods are likely to
cause unique immune responses in multiple areas of the host as they disseminate and colonize
their preferred tissues. Future study of foodborne infections should take into account the unique
role of local and systemic mediators not traditionally considered to be a major factor in bacterial
pathogenesis.
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Figure 6.1 Hypothesis: Overproduction of PGE2 in the BALB liver decreases PMN killing
efficiency
BALB and B6 mice both consume Lm, which invades the intestine and disseminates to the liver
in similar numbers in both mice. The bacterial insult triggers recruitment of PMN to the livers of
both mice that emerge from the bone marrow similarly able to kill bacteria In the BALB mouse,
however, the arrival of the bacteria triggers overproduction of PGE2 that is not observed in the
B6 mouse. This PGE2 then causes a reduction in multiple parameters of PMN function, leading
to a decrease in overall PMN killing efficiency in the BALB liver.
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Appendix I: List of abbreviations
AMP/ c-di-AMP= adenosine monophosphate/ cyclic-di-adenosine monophosphate
BALB/ BA= BALBcBy/J mouse, a strain of mouse that is susceptible to Listeria infection
B6= C57BL/6J mouse, a strain of mouse that is relatively resistant to Listeria infection
BHI= brain heart infusion (broth or agar)
CD (e.g. CD4, CD86)= cluster of differentiation
CFU= colony forming units
COX-2= cyclooxygenase enzyme 2
DHR= dihydrorhodamine 123
DNA= deoxyribonucleic acid
dpi= days post infection
EIA= enzyme immunoassay
ELISA= enzyme-linked immunosorbent assay
FACS= fluorescence activated cell sorting
hpi= hours post infection
IFN= interferon
IFNAR= interferon alpha/beta receptor
IFNγR= interferon gamma receptor
i.g.= intragastric
Inl (A/B)= internalin
KC= Kupffer cell
IL= interleukin
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i.p.= intraperitoneal
i.v.= intravenous
JAK= Janus kinase
Lm = Listeria monocytogenes
LO/ LOX= lipoxygenase
LSEC= liver sinusoidal endothelial cell
LTB4= leukotriene B4
M= molar (micro, nano)
mΦ= macrophage
MAPK= mitogen-activated protein kinase
MFI= mean fluorescence intensity
MHC= major histocompatibility complex
mPGES= microsomal prostaglandin E synthase
mpi= minutes post infection
NI= not infected
NK cell= natural killer cell
NSAID= non-steroidal anti-inflammatory drug
PG/ PGE2= prostaglandin/ prostaglandin E2
PLA2= phospholipase A2
PMN= neutrophil polymorphonuclear leukocyte
PrfA= positive regulatory factor A
RNA= ribonucleic acid
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ROS= reactive oxygen species
SD= standard deviation
STAT= signal transducer and activator of transcription
STING= stimulator of interferon-related genes
TLR= toll-like receptor
TRAIL= tumor necrosis factor alpha apoptosis-inducing ligand
TNFα= tumor necrosis factor alpha
TYK= tyrosine kinase
UTR= untranslated region
VCAM= vascular cell adhesion molecule
VLA4= very late antigen 4
WT= wild-type
α= alpha
β= beta
∆= delta, deletion
γ= gamma
κ= kappa
μ= micro
σ= sigma
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